{
  "bladder_cancer": [
    {
      "row_id": "3070MO",
      "regimen": "LY3866288",
      "drugs": [
        "LY3866288"
      ],
      "biomarkers": [
        "FGFR3"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": "FORAGER-1"
    },
    {
      "row_id": "LBA110",
      "regimen": "nivolumab + visugromab",
      "drugs": [
        "nivolumab",
        "visugromab"
      ],
      "modality": [
        "IO"
      ],
      "population": "MIBC",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "LBA112",
      "regimen": "gemcitabine intravesical system (TAR-200) + cetrelimab",
      "drugs": [
        "gemcitabine",
        "cetrelimab"
      ],
      "modality": [
        "Intravesical"
      ],
      "population": "MIBC",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "SunRISe-4",
      "biomarkers": []
    },
    {
      "row_id": "ROW_70",
      "regimen": "platinum-based chemotherapy → avelumab maintenance",
      "drugs": [
        "platinum-based chemotherapy",
        "avelumab"
      ],
      "modality": [
        "Chemotherapy",
        "Maintenance"
      ],
      "population": "Other",
      "line": "Maintenance",
      "phase": "Phase 2",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "3071MO",
      "regimen": "Disitamab Vedotin + Tislelizumab",
      "drugs": [
        "Disitamab Vedotin",
        "Tislelizumab",
        "disitamab vedotin",
        "tislelizumab"
      ],
      "modality": [
        "ADC",
        "IO"
      ],
      "population": "UTUC",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "DISTINCT-I",
      "biomarkers": []
    },
    {
      "row_id": "LBA108",
      "regimen": "durvalumab + BCG",
      "drugs": [
        "durvalumab",
        "BCG"
      ],
      "modality": [
        "IO",
        "Intravesical"
      ],
      "population": "NMIBC",
      "line": "Not specified",
      "phase": "Phase 3",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "3068O",
      "regimen": "nivolumab vs placebo",
      "drugs": [
        "nivolumab"
      ],
      "modality": [
        "IO"
      ],
      "population": "MIBC",
      "line": "Adjuvant",
      "phase": "Approved",
      "trial_id": "CheckMate 274",
      "biomarkers": []
    },
    {
      "row_id": "3069MO",
      "regimen": "durvalumab + neoadjuvant chemotherapy",
      "drugs": [
        "durvalumab"
      ],
      "modality": [
        "IO",
        "Chemotherapy"
      ],
      "population": "MIBC",
      "line": "Perioperative",
      "phase": "Not specified",
      "trial_id": "NIAGARA",
      "biomarkers": []
    },
    {
      "row_id": "LBA107",
      "regimen": "atezolizumab + BCG",
      "drugs": [
        "atezolizumab",
        "BCG"
      ],
      "modality": [
        "IO",
        "Intravesical"
      ],
      "population": "NMIBC",
      "line": "Not specified",
      "phase": "Phase 3",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "3072MO",
      "regimen": "Datopotamab deruxtecan + rilvegostomig",
      "drugs": [
        "Datopotamab deruxtecan",
        "rilvegostomig"
      ],
      "modality": [
        "ADC",
        "IO"
      ],
      "population": "mUC",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "TROPION-PanTumor",
      "biomarkers": []
    },
    {
      "row_id": "3091P",
      "regimen": "Artificial Intelligence Predicts",
      "drugs": [],
      "modality": [],
      "population": "MIBC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "3111eP",
      "regimen": "enfortumab vedotin",
      "drugs": [
        "enfortumab vedotin"
      ],
      "population": "mUC",
      "phase": "Not specified",
      "trial_id": "3111eP",
      "biomarkers": []
    },
    {
      "row_id": "3083P",
      "regimen": "avelumab + sacituzumab govitecan",
      "drugs": [
        "avelumab",
        "sacituzumab govitecan"
      ],
      "population": "mUC",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": "3083P",
      "biomarkers": []
    },
    {
      "row_id": "3085P",
      "regimen": "tislelizumab combined with disitamab vedotin",
      "drugs": [
        "tislelizumab",
        "disitamab vedotin"
      ],
      "population": "Other",
      "phase": "Phase 2",
      "trial_id": "3085P",
      "biomarkers": []
    },
    {
      "row_id": "LBA2",
      "regimen": "enfortumab vedotin + pembrolizumab",
      "drugs": [
        "enfortumab vedotin",
        "pembrolizumab",
        "cisplatin"
      ],
      "population": "MIBC",
      "line": "Perioperative",
      "phase": "Not specified",
      "trial_id": "LBA2",
      "biomarkers": []
    },
    {
      "row_id": "3084P",
      "regimen": "Durvalumab +/- tremelimumab + ddMVAC",
      "drugs": [
        "Durvalumab",
        "tremelimumab",
        "ddMVAC",
        "durvalumab"
      ],
      "population": "MIBC",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "3084P",
      "biomarkers": []
    },
    {
      "row_id": "3121eP",
      "regimen": "Durvalumab plus Platin-based Chemotherapy",
      "drugs": [
        "Durvalumab",
        "durvalumab"
      ],
      "population": "MIBC",
      "line": "Perioperative",
      "phase": "Not specified",
      "trial_id": "3121eP",
      "biomarkers": []
    },
    {
      "row_id": "3089P",
      "regimen": "enfortumab vedotin and pembrolizumab",
      "drugs": [
        "enfortumab vedotin",
        "pembrolizumab"
      ],
      "population": "mUC",
      "phase": "Not specified",
      "trial_id": "3089P",
      "biomarkers": []
    },
    {
      "row_id": "3102P",
      "regimen": "enfortumab vedotin and pembrolizumab",
      "drugs": [
        "enfortumab vedotin",
        "pembrolizumab"
      ],
      "biomarkers": [
        "FGFR3",
        "ERBB2",
        "HER2"
      ],
      "population": "mUC",
      "phase": "Not specified",
      "trial_id": "3102P"
    },
    {
      "row_id": "3098P",
      "regimen": "Fexagratinib",
      "drugs": [
        "Fexagratinib"
      ],
      "biomarkers": [
        "FGFR3"
      ],
      "population": "mUC",
      "phase": "Not specified",
      "trial_id": "3098P"
    },
    {
      "row_id": "3095P",
      "regimen": "enfortumab vedotin",
      "drugs": [
        "enfortumab vedotin"
      ],
      "biomarkers": [
        "ERBB2",
        "Nectin-4",
        "HER2"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "3095P"
    },
    {
      "row_id": "3088P",
      "regimen": "TAR-200",
      "drugs": [
        "TAR-200",
        "cisplatin"
      ],
      "population": "NMIBC",
      "phase": "Phase 2b",
      "trial_id": "3088P",
      "biomarkers": []
    },
    {
      "row_id": "3076P",
      "regimen": "RC48-ADC combined with tislelizumab",
      "drugs": [
        "RC48-ADC",
        "tislelizumab",
        "disitamab vedotin"
      ],
      "biomarkers": [
        "HER2"
      ],
      "population": "MIBC",
      "line": "Neoadjuvant",
      "phase": "Phase Ib/II",
      "trial_id": "3076P"
    },
    {
      "row_id": "3119eP",
      "regimen": "Bacillus Calmette-Guerin",
      "drugs": [
        "BCG"
      ],
      "population": "NMIBC",
      "phase": "Not specified",
      "trial_id": "3119eP",
      "biomarkers": []
    },
    {
      "row_id": "3093P",
      "regimen": "Sacituzumab Govitecan alone and with pembrolizumab",
      "drugs": [
        "Sacituzumab Govitecan",
        "pembrolizumab",
        "sacituzumab govitecan"
      ],
      "population": "MIBC",
      "phase": "Not specified",
      "trial_id": "3093P",
      "biomarkers": []
    },
    {
      "row_id": "3134eTiP",
      "regimen": "neoadjuvant Systemic Therapies",
      "drugs": [],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "3134eTiP",
      "biomarkers": []
    },
    {
      "row_id": "3096P",
      "regimen": "Immunotherapy",
      "drugs": [],
      "population": "mUC",
      "phase": "Not specified",
      "trial_id": "3096P",
      "biomarkers": []
    },
    {
      "row_id": "3108P",
      "regimen": "Enfortumab Vedotin",
      "drugs": [
        "enfortumab vedotin"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "3108P",
      "biomarkers": []
    },
    {
      "row_id": "3112eP",
      "regimen": "enfortumab vedotin",
      "drugs": [
        "enfortumab vedotin"
      ],
      "population": "mUC",
      "phase": "Not specified",
      "trial_id": "EVOLUTE",
      "biomarkers": []
    },
    {
      "row_id": "3078P",
      "regimen": "sasanlimab + Bacillus Calmette-Guerin",
      "drugs": [
        "sasanlimab",
        "Bacillus Calmette-Guerin"
      ],
      "population": "MIBC",
      "line": "1L",
      "phase": "Phase 3",
      "trial_id": "CREST",
      "biomarkers": []
    },
    {
      "row_id": "3128eP",
      "regimen": "Neoadjuvant Chemo-Immunotherapy",
      "biomarkers": [
        "PD-L1"
      ],
      "population": "MIBC",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "AURA",
      "drugs": []
    },
    {
      "row_id": "3075P",
      "regimen": "Adjuvant Therapy",
      "population": "UTUC",
      "line": "Adjuvant",
      "phase": "Not specified",
      "trial_id": "CURATE-UTUC",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "3099P",
      "regimen": "BCG",
      "population": "NMIBC",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "3116eP",
      "regimen": "advanced urothelial carcinoma",
      "population": "MIBC",
      "phase": "Not specified",
      "trial_id": "JAV",
      "drugs": [
        "avelumab"
      ],
      "biomarkers": []
    },
    {
      "row_id": "3073P",
      "regimen": "enfortumab vedotin + pembrolizumab",
      "drugs": [
        "enfortumab vedotin",
        "pembrolizumab"
      ],
      "population": "mUC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "3087P",
      "regimen": "enfortumab vedotin + pembrolizumab",
      "drugs": [
        "enfortumab vedotin",
        "pembrolizumab"
      ],
      "biomarkers": [
        "NECTIN4",
        "Nectin-4"
      ],
      "population": "mUC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "3090P",
      "regimen": "enfortumab vedotin",
      "drugs": [
        "enfortumab vedotin"
      ],
      "biomarkers": [
        "NECTIN4",
        "Nectin-4"
      ],
      "population": "mUC",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "3082P",
      "regimen": "Spatial Transcriptomics",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "SOGUG-AUREA",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "3126eP",
      "regimen": "PET-CT",
      "population": "MIBC",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "3092P",
      "regimen": "erdafitinib",
      "drugs": [
        "erdafitinib"
      ],
      "population": "mUC",
      "line": "1L",
      "phase": "Phase 3",
      "trial_id": "THOR",
      "biomarkers": []
    },
    {
      "row_id": "3135eTiP",
      "regimen": "intismeran autogene + Bacillus Calmette-Guerin",
      "drugs": [
        "intismeran autogene",
        "Bacillus Calmette-Guerin"
      ],
      "population": "NMIBC",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": "INTerpath-011",
      "biomarkers": []
    },
    {
      "row_id": "3120eP",
      "regimen": "Antibody-Drug Conjugates",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_907",
      "regimen": "adjuvant therapy",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_990",
      "regimen": "Not specified",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_1120",
      "regimen": "frontline therapy",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_1224",
      "regimen": "trimodality therapy",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_1240",
      "regimen": "neoadjuvant therapy",
      "population": "MIBC",
      "phase": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "3109eP",
      "regimen": "avelumab first-line maintenance",
      "drugs": [
        "avelumab"
      ],
      "population": "mUC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "3122eP",
      "regimen": "platinum-based treatment",
      "population": "mUC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "3106P",
      "regimen": "perioperative chemo-immunotherapy with Durvalumab",
      "drugs": [
        "Durvalumab",
        "durvalumab"
      ],
      "population": "MIBC",
      "line": "Perioperative",
      "phase": "Phase 2",
      "trial_id": "SAKK 06/17",
      "biomarkers": []
    },
    {
      "row_id": "3107P",
      "regimen": "intravesical recombinant BCG followed by perioperative chemo-immunotherapy",
      "population": "MIBC",
      "line": "Perioperative",
      "phase": "Not specified",
      "trial_id": "SAKK 06/19",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "3100P",
      "regimen": "Enfortumab Vedotin Plus Pembrolizumab Therapy",
      "drugs": [
        "enfortumab vedotin",
        "pembrolizumab"
      ],
      "biomarkers": [
        "NECTIN-4",
        "Nectin-4"
      ],
      "population": "mUC",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "3129eP",
      "regimen": "neoadjuvant chemotherapy",
      "population": "MIBC",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "3097P",
      "regimen": "AI Prediction Model",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "3127eP",
      "regimen": "Bulumtatug Fuvedotin combined with Toripalimab",
      "drugs": [
        "Bulumtatug Fuvedotin",
        "Toripalimab",
        "toripalimab"
      ],
      "population": "mUC",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": [
        "Nectin-4"
      ]
    },
    {
      "row_id": "3077P",
      "regimen": "Enfortumab vedotin with pembrolizumab",
      "drugs": [
        "enfortumab vedotin",
        "pembrolizumab"
      ],
      "population": "mUC",
      "phase": "Not specified",
      "trial_id": "UNITE",
      "biomarkers": []
    },
    {
      "row_id": "3105P",
      "regimen": "Sex-Associated Outcomes in Enfortumab Vedotin-Treated",
      "drugs": [
        "enfortumab vedotin"
      ],
      "population": "mUC",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": [
        "Nectin-4"
      ]
    },
    {
      "row_id": "3074P",
      "regimen": "enfortumab vedotin with or without pembrolizumab",
      "drugs": [
        "enfortumab vedotin",
        "pembrolizumab",
        "cisplatin"
      ],
      "population": "MIBC",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": "EV-103 Cohort K",
      "biomarkers": []
    },
    {
      "row_id": "3115eP",
      "regimen": "avelumab, pembrolizumab or enfortumab vedotin",
      "drugs": [
        "avelumab",
        "pembrolizumab",
        "enfortumab vedotin"
      ],
      "population": "mUC",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "3079P",
      "regimen": "Disitamab Vedotin plus BCG",
      "drugs": [
        "Disitamab Vedotin",
        "BCG",
        "disitamab vedotin"
      ],
      "biomarkers": [
        "HER2"
      ],
      "population": "NMIBC",
      "phase": "Phase 2",
      "trial_id": "Formula-01"
    },
    {
      "row_id": "3086P",
      "regimen": "Organ-Preserving Therapy",
      "population": "MIBC",
      "phase": "Phase 2",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "3103P",
      "regimen": "Chemotherapy plus Toripalimab as Neoadjuvant Therapy",
      "drugs": [
        "Toripalimab",
        "toripalimab"
      ],
      "population": "UTUC",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "WUTSUP-01",
      "biomarkers": []
    },
    {
      "row_id": "3081P",
      "regimen": "Bladder Preservation Therapy in Combination with Atezolizumab and Radiation therapy",
      "drugs": [
        "Atezolizumab",
        "atezolizumab"
      ],
      "population": "MIBC",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "3114eP",
      "regimen": "Disitamab Vedotin Plus Toripalimab Treatment",
      "drugs": [
        "Disitamab Vedotin",
        "Toripalimab",
        "disitamab vedotin",
        "toripalimab"
      ],
      "biomarkers": [
        "HER-2"
      ],
      "population": "MIBC",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "3110eP",
      "regimen": "ctDNA-Guided Atezolizumab Adjuvant Therapy",
      "drugs": [
        "Atezolizumab",
        "atezolizumab"
      ],
      "population": "MIBC",
      "line": "Adjuvant",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "3104P",
      "regimen": "First-line therapy",
      "population": "mUC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "NCDB Analysis",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "967P",
      "regimen": "Nectin-4-targeting antibody-drug conjugate CRB-701",
      "drugs": [
        "CRB-701",
        "SYS6002"
      ],
      "population": "Other",
      "phase": "Phase 1/2",
      "trial_id": "SYS6002",
      "biomarkers": [
        "Nectin-4"
      ]
    },
    {
      "row_id": "LBA7",
      "regimen": "Disitamab vedotin + toripalimab versus chemotherapy",
      "drugs": [
        "Disitamab vedotin",
        "toripalimab",
        "chemotherapy",
        "disitamab vedotin"
      ],
      "population": "mUC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "LBA7",
      "biomarkers": [
        "HER2"
      ]
    },
    {
      "row_id": "ROW_1841",
      "regimen": "optimal 1L treatment",
      "population": "mHSPC",
      "line": "1L",
      "phase": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_1948",
      "regimen": "Optimising 1L treatment",
      "population": "mHSPC",
      "line": "1L",
      "phase": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_2777",
      "regimen": "Optimising 1L treatment",
      "population": "mUC",
      "line": "1L",
      "phase": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_2919",
      "population": "mUC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_3207",
      "population": "MIBC",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1766eP",
      "biomarkers": [
        "FGFR"
      ],
      "population": "NMIBC",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": []
    },
    {
      "row_id": "ROW_3477",
      "population": "mUC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1513O",
      "regimen": "GDF-15 neutralization + nivolumab",
      "drugs": [
        "GDF-15",
        "nivolumab"
      ],
      "population": "Other",
      "line": "3L",
      "phase": "Phase 2",
      "trial_id": "GDFATHER-01",
      "biomarkers": []
    },
    {
      "row_id": "52eP",
      "regimen": "PF-08052667",
      "drugs": [
        "PF-08052667"
      ],
      "modality": [
        "ADC"
      ],
      "population": "NMIBC",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "ROW_3935",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_4092",
      "biomarkers": [
        "emerging biomarkers"
      ],
      "population": "mUC",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": []
    },
    {
      "row_id": "LBA8",
      "regimen": "circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo",
      "drugs": [
        "atezolizumab"
      ],
      "modality": [
        "Adjuvant"
      ],
      "population": "MIBC",
      "line": "Adjuvant",
      "phase": "Phase 3",
      "trial_id": "IMvigor011",
      "biomarkers": []
    },
    {
      "row_id": "25P",
      "regimen": "KAT2A-mediated MECP2 lactylation",
      "drugs": [],
      "biomarkers": [
        "KAT2A",
        "MECP2",
        "FGF1"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "KAT2A"
    },
    {
      "row_id": "23P",
      "regimen": "HDACs inhibitor sensitizes the efficacy of cisplatin",
      "drugs": [
        "cisplatin"
      ],
      "biomarkers": [
        "H3K18la",
        "DHRS2"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "HDACs"
    },
    {
      "row_id": "CN68",
      "regimen": "Chain Mediating Effect of Family APGAR and Psychosocial Adjustment",
      "drugs": [],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "Family APGAR",
      "biomarkers": []
    },
    {
      "row_id": "LBA111",
      "regimen": "upfront Magnetic Resonance Imaging versus Transurethral Resection",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "mUC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "BladderPath"
    },
    {
      "row_id": "3123eP",
      "regimen": "first-line treatment strategies",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "mUC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "3094P",
      "regimen": "enfortumab vedotin + pembrolizumab",
      "drugs": [
        "enfortumab vedotin",
        "pembrolizumab"
      ],
      "biomarkers": [],
      "modality": [
        "ADC"
      ],
      "population": "mUC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "UNITE"
    },
    {
      "row_id": "3132eP",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "3130eP",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "mUC",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "3101P",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "mUC",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1284",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1791",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1868",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1884",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1922",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_2063",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2326P",
      "regimen": "Systemic Therapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "MIBC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2326P"
    },
    {
      "row_id": "ROW_2203",
      "regimen": "Not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_2203"
    },
    {
      "row_id": "ROW_2254",
      "regimen": "Not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_2254"
    },
    {
      "row_id": "ROW_2255",
      "regimen": "Not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_2255"
    },
    {
      "row_id": "ROW_2288",
      "regimen": "Combinations with ADCs",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "ADC"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_2288"
    },
    {
      "row_id": "ROW_2700",
      "regimen": "Not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_2700"
    },
    {
      "row_id": "ROW_2702",
      "regimen": "Not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_2702"
    },
    {
      "row_id": "ROW_2705",
      "regimen": "Not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_2705"
    },
    {
      "row_id": "ROW_2874",
      "regimen": "Not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_2874"
    },
    {
      "row_id": "ROW_3093",
      "regimen": "Not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_3093"
    },
    {
      "row_id": "24P",
      "regimen": "Cancer cell reprogramming",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "24P"
    },
    {
      "row_id": "ROW_3302",
      "regimen": "Microbiome",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_3302"
    },
    {
      "row_id": "ROW_3401",
      "regimen": "Shared decision-making in la/mUC",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "mUC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_3401"
    },
    {
      "row_id": "ROW_3455",
      "regimen": "Novel imaging",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_3455"
    },
    {
      "row_id": "3052eP",
      "regimen": "KDM6A deficiency assessment",
      "drugs": [],
      "biomarkers": [
        "KDM6A"
      ],
      "modality": [],
      "population": "mUC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "3052eP"
    },
    {
      "row_id": "245eP",
      "regimen": "Urine biomarkers assessment",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "245eP"
    },
    {
      "row_id": "62eP",
      "regimen": "Metabolic regulation of metastasis",
      "drugs": [],
      "biomarkers": [
        "ARHGDIB"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "62eP"
    },
    {
      "row_id": "ROW_3677",
      "regimen": "Clinical insights in MIBC",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "MIBC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_3677"
    },
    {
      "row_id": "ROW_3749",
      "regimen": "Real-world evidence in la/mUC",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "mUC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_3749"
    },
    {
      "row_id": "ROW_4187",
      "regimen": "Soluble biomarkers",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_4187"
    },
    {
      "row_id": "ROW_4245",
      "regimen": "Epigenetics and spatial genomics",
      "trial_id": "ROW_4245",
      "drugs": [],
      "biomarkers": []
    }
  ],
  "lung_cancer": [
    {
      "row_id": "ROW_151",
      "regimen": "emerging therapies for lung cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_151"
    },
    {
      "row_id": "ROW_154",
      "regimen": "DLL3 targeting in lung cancers of neuroendocrine origin",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_154"
    },
    {
      "row_id": "2986eP",
      "regimen": "identifying a population at risk in lung cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2986eP"
    },
    {
      "row_id": "3172eP",
      "regimen": "predictive value of LIPI score in immunotherapy response",
      "drugs": [],
      "biomarkers": [
        "LIPI"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "3172eP"
    },
    {
      "row_id": "1882P",
      "regimen": "population-level real-world evidence in lung cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1882P"
    },
    {
      "row_id": "1",
      "regimen": "Combined Blockade of KRAS and PRMT5",
      "drugs": [
        "KRAS",
        "PRMT5"
      ],
      "biomarkers": [
        "KRAS"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "2248P"
    },
    {
      "row_id": "2",
      "regimen": "First-Line anti-EGFR Therapy",
      "drugs": [
        "anti-EGFR"
      ],
      "biomarkers": [
        "DNA Methylation"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "817P"
    },
    {
      "row_id": "3",
      "regimen": "toripalimab, cetuximab plus FOLFIRI",
      "drugs": [
        "toripalimab",
        "cetuximab",
        "FOLFIRI"
      ],
      "biomarkers": [
        "RAS",
        "BRAF"
      ],
      "modality": [
        "IO",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": "866eP"
    },
    {
      "row_id": "4",
      "regimen": "HRS-4642 Combined with Gemcitabine and Nab-paclitaxel",
      "drugs": [
        "HRS-4642",
        "Gemcitabine",
        "Nab-paclitaxel"
      ],
      "biomarkers": [
        "KRAS-G12D"
      ],
      "modality": [
        "ADC",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 1b/2",
      "trial_id": "2215O"
    },
    {
      "row_id": "5",
      "regimen": "DS-3939 in advanced/metastatic solid tumors",
      "drugs": [
        "DS-3939"
      ],
      "biomarkers": [
        "TA-MUC1"
      ],
      "modality": [
        "ADC"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "917O"
    },
    {
      "row_id": "6",
      "regimen": "Conversion Therapy With Encorafenib + Cetuximab",
      "drugs": [
        "Encorafenib",
        "Cetuximab"
      ],
      "biomarkers": [
        "BRAF V600E"
      ],
      "modality": [
        "TKI",
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "880eP"
    },
    {
      "row_id": "7",
      "regimen": "Predictive biomarker to anti-EGFR therapy",
      "drugs": [
        "anti-EGFR"
      ],
      "biomarkers": [
        "Lactate dehydrogenase",
        "RAS",
        "BRAF"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "814P"
    },
    {
      "row_id": "8",
      "regimen": "Optimised adaptive strategies with systemic therapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_2457"
    },
    {
      "row_id": "9",
      "regimen": "Frontline Anti-VEGF and Anti-EGFR Exposure",
      "drugs": [
        "Trifluridine",
        "Tipiracil",
        "Regorafenib"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "792P"
    },
    {
      "row_id": "10",
      "regimen": "Welcome and introductions",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_2470"
    },
    {
      "row_id": "11",
      "regimen": "systemic mitochondrial alterations in lung cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "224eP"
    },
    {
      "row_id": "12",
      "regimen": "DNA mutation and methylation evolution in lung adenocarcinoma",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "3042eP"
    },
    {
      "row_id": "13",
      "regimen": "targeted therapy in BRAF-mutant glioblastomas",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "687P"
    },
    {
      "row_id": "14",
      "regimen": "efficacy of second-line BRAF/MEK inhibitors",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "2L",
      "phase": "Not specified",
      "trial_id": "1646P"
    },
    {
      "row_id": "15",
      "regimen": "clinical efficacy of PD-1/CTLA-4 bispecific antibody",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "18P"
    },
    {
      "row_id": "16",
      "regimen": "external validation of Rachel score",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1721P"
    },
    {
      "row_id": "17",
      "regimen": "interlesional heterogeneity of EGFR mutations",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "249eP"
    },
    {
      "row_id": "18",
      "regimen": "real-world treatment patterns in NTRK+ tumors",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "171P"
    },
    {
      "row_id": "19",
      "regimen": "efficacy and safety of anlotinib plus sintilimab",
      "drugs": [
        "Anlotinib",
        "Sintilimab"
      ],
      "biomarkers": [],
      "modality": [
        "TKI",
        "IO"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Phase 2",
      "trial_id": "2991P"
    },
    {
      "row_id": "2073eP",
      "regimen": "Adherence to Tumor Board Recommendations",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2073eP"
    },
    {
      "row_id": "1927P",
      "regimen": "Tracking Myeloid Cells Variation",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1927P"
    },
    {
      "row_id": "2055eP",
      "regimen": "Occupational Exposure to Carcinogens",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2055eP"
    },
    {
      "row_id": "ROW_655",
      "regimen": "Diagnosis and treatment of G3 lung NET",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_655"
    },
    {
      "row_id": "1897P",
      "regimen": "PD-1/IL-2 Bispecific Antibody",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1897P"
    },
    {
      "row_id": "2978P",
      "regimen": "AI-defined Lung Nodule Malignancy Score",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "2978P"
    },
    {
      "row_id": "ROW_719",
      "regimen": "Lung",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_719"
    },
    {
      "row_id": "ROW_730",
      "regimen": "Invited Discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_730"
    },
    {
      "row_id": "ROW_733",
      "regimen": "Q&A & discussion",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_733"
    },
    {
      "row_id": "ROW_734",
      "regimen": "Conclusion remarks",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_734"
    },
    {
      "row_id": "2975P",
      "regimen": "Barriers to lung cancer screening",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2975P"
    },
    {
      "row_id": "1873P",
      "regimen": "Ipilimumab Plus Nivolumab With or Without Chemotherapy",
      "drugs": [
        "Ipilimumab",
        "Nivolumab",
        "nivolumab"
      ],
      "biomarkers": [],
      "modality": [
        "IO",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1873P"
    },
    {
      "row_id": "1925P",
      "regimen": "Single cell RNA-sequencing reveals IGFBP3+ CAFs",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1925P"
    },
    {
      "row_id": "1968P",
      "regimen": "MedSR (Median Short Fragment Ratio)",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1968P"
    },
    {
      "row_id": "ROW_796",
      "regimen": "Invited Discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_796"
    },
    {
      "row_id": "1951P",
      "regimen": "Companion diagnostic assay for c-Met protein overexpression",
      "drugs": [
        "telisotuzumab vedotin"
      ],
      "biomarkers": [
        "c-Met"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1951P"
    },
    {
      "row_id": "ROW_803",
      "regimen": "Harnessing the immune system for cancer prevention",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_803"
    },
    {
      "row_id": "2077eP",
      "regimen": "Evaluation of efficacy differences among three treatment modalities",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2077eP"
    },
    {
      "row_id": "2072eP",
      "regimen": "Predicting Brain Metastasis at the Time of Diagnosis",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2072eP"
    },
    {
      "row_id": "ROW_866",
      "regimen": "Relentless research for novel treatment options",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_866"
    },
    {
      "row_id": "1906P",
      "regimen": "first-line immune checkpoint inhibitors",
      "drugs": [
        "immune checkpoint inhibitors"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "1906P"
    },
    {
      "row_id": "1900P",
      "regimen": "high-intensity interval training",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1900P"
    },
    {
      "row_id": "2000P",
      "regimen": "selective RET inhibitor",
      "drugs": [
        "selective RET inhibitor"
      ],
      "biomarkers": [],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2000P"
    },
    {
      "row_id": "2050eP",
      "regimen": "analysis of prognostic factors",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2050eP"
    },
    {
      "row_id": "2069eP",
      "regimen": "molecular targeted agents",
      "drugs": [
        "molecular targeted agents"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2069eP"
    },
    {
      "row_id": "2776P",
      "regimen": "DLL3-targeting antibody therapies",
      "drugs": [
        "DLL3-targeting antibody therapies"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2776P"
    },
    {
      "row_id": "2987O",
      "regimen": "Dabrafenib Plus Trametinib",
      "drugs": [
        "Dabrafenib",
        "Trametinib"
      ],
      "biomarkers": [],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2987O"
    },
    {
      "row_id": "3194eP",
      "regimen": "short films as tool in lung cancer communication",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "3194eP"
    },
    {
      "row_id": "2070eP",
      "regimen": "Pemetrexed-Based Chemo-Immunotherapy",
      "drugs": [
        "Pemetrexed"
      ],
      "biomarkers": [
        "TTF-1",
        "PD-L1"
      ],
      "modality": [
        "IO",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2070eP"
    },
    {
      "row_id": "1913P",
      "regimen": "targeted therapy",
      "drugs": [
        "ctDNA Testing"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1913P"
    },
    {
      "row_id": "1956P",
      "regimen": "osimertinib then chemotherapy",
      "drugs": [
        "osimertinib",
        "chemotherapy"
      ],
      "biomarkers": [
        "EGFR"
      ],
      "modality": [
        "TKI",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "3L",
      "phase": "Not specified",
      "trial_id": "1956P"
    },
    {
      "row_id": "1832P",
      "regimen": "remodel lung adenocarcinoma immune microenvironment",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1832P"
    },
    {
      "row_id": "2016P",
      "regimen": "neuropsychological assessment and brain imaging",
      "drugs": [
        "atezolizumab"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2016P"
    },
    {
      "row_id": "3175eP",
      "regimen": "not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ICARUS-LUNG01"
    },
    {
      "row_id": "ROW_1216",
      "regimen": "not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "not specified"
    },
    {
      "row_id": "2065eP",
      "regimen": "not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "not specified"
    },
    {
      "row_id": "1980P",
      "regimen": "not specified",
      "drugs": [],
      "biomarkers": [
        "ALK",
        "TMB"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "ABP"
    },
    {
      "row_id": "1814eP",
      "regimen": "not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "not specified"
    },
    {
      "row_id": "1866P",
      "regimen": "camrelizumab plus famitinib",
      "drugs": [
        "camrelizumab",
        "famitinib"
      ],
      "biomarkers": [],
      "modality": [
        "IO",
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "CAPSTONE"
    },
    {
      "row_id": "2066eP",
      "regimen": "not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "not specified"
    },
    {
      "row_id": "1977P",
      "regimen": "not specified",
      "drugs": [
        "SGR-5573"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "not specified"
    },
    {
      "row_id": "1898P",
      "regimen": "not specified",
      "drugs": [
        "pembrolizumab"
      ],
      "biomarkers": [
        "PD-1"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "not specified"
    },
    {
      "row_id": "2053eP",
      "regimen": "not specified",
      "drugs": [],
      "biomarkers": [
        "EGFR",
        "ALK"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "WAYFIND-R"
    },
    {
      "row_id": "ROW_1320",
      "regimen": "not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "not specified"
    },
    {
      "row_id": "ROW_1322",
      "regimen": "not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "not specified"
    },
    {
      "row_id": "2009P",
      "regimen": "chemotherapy and tyrosine kinase inhibition",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Chemotherapy",
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "not specified"
    },
    {
      "row_id": "ROW_1369",
      "regimen": "not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "not specified"
    },
    {
      "row_id": "3193eP",
      "regimen": "not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "not specified"
    },
    {
      "row_id": "1961P",
      "regimen": "osimertinib monotherapy",
      "drugs": [
        "osimertinib"
      ],
      "biomarkers": [
        "TP53"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "not specified"
    },
    {
      "row_id": "2780P",
      "regimen": "not specified",
      "drugs": [
        "BL0020"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": "not specified"
    },
    {
      "row_id": "ROW_1421",
      "regimen": "not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "not specified"
    },
    {
      "row_id": "1830P",
      "regimen": "not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "not specified"
    },
    {
      "row_id": "1793P",
      "regimen": "not specified",
      "drugs": [],
      "biomarkers": [
        "EGFR"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "not specified"
    },
    {
      "row_id": "2040eP",
      "regimen": "treatment-naive, driver-negative metastatic lung cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2040eP"
    },
    {
      "row_id": "1805eP",
      "regimen": "microwave ablation versus lobectomy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1805eP"
    },
    {
      "row_id": "1812eP",
      "regimen": "IO treatment",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1812eP"
    },
    {
      "row_id": "2047eP",
      "regimen": "large language models in multidisciplinary planning",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2047eP"
    },
    {
      "row_id": "2049eP",
      "regimen": "osimertinib rechallenge",
      "drugs": [
        "osimertinib"
      ],
      "biomarkers": [],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2049eP"
    },
    {
      "row_id": "CN158",
      "regimen": "association between genetic risk and lung cancer risk",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "CN158"
    },
    {
      "row_id": "1800P",
      "regimen": "lower CT nodule thresholds in lung cancer screening",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1800P"
    },
    {
      "row_id": "1909P",
      "regimen": "radiological and molecular patterns of metastatic growth",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1909P"
    },
    {
      "row_id": "1892P",
      "regimen": "treatment and prognosis of lung cancer in young patients",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1892P"
    },
    {
      "row_id": "2008P",
      "regimen": "frontline TKIs",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2008P"
    },
    {
      "row_id": "1799P",
      "regimen": "uniportal video-assisted thoracoscopic surgery",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1799P"
    },
    {
      "row_id": "1903P",
      "regimen": "antibiotic exposure before or during immune checkpoint inhibitor therapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1903P"
    },
    {
      "row_id": "ROW_1686",
      "regimen": "invited discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_1686"
    },
    {
      "row_id": "2838P",
      "regimen": "trastuzumab deruxtecan-induced interstitial lung disease",
      "drugs": [
        "trastuzumab deruxtecan"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2838P"
    },
    {
      "row_id": "LBA84",
      "regimen": "GFH375 monotherapy",
      "drugs": [
        "GFH375"
      ],
      "biomarkers": [
        "KRAS"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "LBA84"
    },
    {
      "row_id": "2186P",
      "regimen": "pre-treatment inflammation and long-term cancer-related fatigue",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2186P"
    },
    {
      "row_id": "853P",
      "regimen": "anti-EGFR resistance mutations",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "853P"
    },
    {
      "row_id": "2371eP",
      "regimen": "scalable implementation of a thoracic tumor functional unit",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2371eP"
    },
    {
      "row_id": "886eP",
      "regimen": "impact of RAS and BRAF mutations on immunotherapy outcomes",
      "drugs": [],
      "biomarkers": [
        "MSI",
        "dMMR"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "886eP"
    },
    {
      "row_id": "ROW_1793",
      "regimen": "optimised adaptive strategies with radiotherapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_1793"
    },
    {
      "row_id": "928P",
      "regimen": "MET-TKI DO-2",
      "drugs": [
        "DO-2"
      ],
      "biomarkers": [
        "MET"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 1",
      "trial_id": "928P"
    },
    {
      "row_id": "882eP",
      "regimen": "Intratumoural IVX037",
      "drugs": [
        "IVX037"
      ],
      "biomarkers": [
        "KRAS"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 1",
      "trial_id": "882eP"
    },
    {
      "row_id": "2884P",
      "regimen": "Multimodal Care for Lung Cancer Patients",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "2884P"
    },
    {
      "row_id": "995P",
      "regimen": "Effect of High-Fat Meal on DO-2",
      "drugs": [
        "DO-2"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "995P"
    },
    {
      "row_id": "2848P",
      "regimen": "Anticoagulation Strategies in Lung Cancer Patients",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "2848P"
    },
    {
      "row_id": "914O",
      "regimen": "HRS-7058 in advanced solid tumors",
      "drugs": [
        "HRS-7058"
      ],
      "biomarkers": [
        "KRAS G12C",
        "KRAS"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 1",
      "trial_id": "914O"
    },
    {
      "row_id": "915O",
      "regimen": "KRAS G12D inhibitor HRS-4642",
      "drugs": [
        "HRS-4642"
      ],
      "biomarkers": [
        "KRAS G12D",
        "KRAS"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 1",
      "trial_id": "915O"
    },
    {
      "row_id": "972P",
      "regimen": "Neladalkib efficacy and safety",
      "drugs": [
        "Neladalkib"
      ],
      "biomarkers": [
        "ALK"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 1",
      "trial_id": "972P"
    },
    {
      "row_id": "2005",
      "regimen": "Implementing shared decision-making",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "2005"
    },
    {
      "row_id": "2006",
      "regimen": "Discussion",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "2006"
    },
    {
      "row_id": "2031",
      "regimen": "Invited Discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "2031"
    },
    {
      "row_id": "1994",
      "regimen": "Invited Discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "1994"
    },
    {
      "row_id": "2067",
      "regimen": "Defining an unfit population",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "2067"
    },
    {
      "row_id": "2106",
      "regimen": "Presentation of case/condition",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "2106"
    },
    {
      "row_id": "2959eP",
      "regimen": "EGFR-targeted monoclonal antibodies",
      "drugs": [],
      "biomarkers": [
        "EGFR"
      ],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "2959eP"
    },
    {
      "row_id": "2961eP",
      "regimen": "Carboplatin dose calculation",
      "drugs": [
        "Carboplatin",
        "carboplatin"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "2961eP"
    },
    {
      "row_id": "1829",
      "regimen": "First-line strategies",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "1829"
    },
    {
      "row_id": "1809",
      "regimen": "Patient supportive care",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "1809"
    },
    {
      "row_id": "932P",
      "regimen": "amivantamab in subjects with aberrant MET and/or EGFR solid tumors",
      "drugs": [
        "Amivantamab"
      ],
      "biomarkers": [
        "MET",
        "EGFR"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 1",
      "trial_id": "Baskets of Baskets"
    },
    {
      "row_id": "1016eTiP",
      "regimen": "LY4066434 in KRAS-mutant solid tumors",
      "drugs": [
        "LY4066434"
      ],
      "biomarkers": [
        "KRAS"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 1",
      "trial_id": "Trial in Progress"
    },
    {
      "row_id": "2932eP",
      "regimen": "lung cancer patient navigator for toxicities management",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2880P",
      "regimen": "effect of physical activities in long-term survivors of lung cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2204eP",
      "regimen": "palliative care management in lung cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "875eP",
      "regimen": "EGFR-, VEGF-inhibitors or no biologics with first line combination chemotherapy",
      "drugs": [],
      "biomarkers": [
        "EGFR"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "835P",
      "regimen": "encorafenib plus cetuximab in BRAF V600E-mutated colorectal carcinoma",
      "drugs": [
        "Encorafenib",
        "Cetuximab"
      ],
      "biomarkers": [
        "BRAF V600E"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": ""
    },
    {
      "row_id": "1558P",
      "regimen": "REGN7075 in patients receiving bispecific antibody",
      "drugs": [
        "REGN7075"
      ],
      "biomarkers": [],
      "modality": [
        "Bispecific"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": ""
    },
    {
      "row_id": "728MO",
      "regimen": "predictive value of low-frequency resistance mutations in anti-EGFR rechallenge",
      "drugs": [],
      "biomarkers": [
        "EGFR"
      ],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2610MO",
      "regimen": "genomic analysis of papillary renal cell carcinoma",
      "drugs": [],
      "biomarkers": [
        "MET"
      ],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "837P",
      "regimen": "impact of TP53 gain of function mutations on clinical outcomes",
      "drugs": [],
      "biomarkers": [
        "TP53"
      ],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2944eP",
      "regimen": "decreased risk of radiation pneumonitis with valsartan",
      "drugs": [
        "Valsartan"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2580eP",
      "regimen": "causal relationships between personality traits and lung cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2373eP",
      "regimen": "barriers undermining lung cancer screening",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2602",
      "regimen": "geographic variation in somatic genomics of lung cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2491",
      "regimen": "summary and take-home messages",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2572",
      "regimen": "tackling EGFR treatment resistance",
      "drugs": [],
      "biomarkers": [
        "EGFR"
      ],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "20",
      "regimen": "patient-derived organoids response to KRAS inhibition",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "78eP"
    },
    {
      "row_id": "1413P",
      "regimen": "Cisplatin Chemoresistance",
      "drugs": [
        "Cisplatin",
        "cisplatin"
      ],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1413P"
    },
    {
      "row_id": "540P",
      "regimen": "post-trastuzumab deruxtecan treatment",
      "drugs": [
        "trastuzumab deruxtecan"
      ],
      "biomarkers": [
        "HER2"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "540P"
    },
    {
      "row_id": "3022eP",
      "regimen": "Radioresistance promotion",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "3022eP"
    },
    {
      "row_id": "1762eP",
      "regimen": "Non-Invasive Tool for Lung Cancer Detection",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Other"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1762eP"
    },
    {
      "row_id": "4086",
      "regimen": "ADC Design and Evaluation",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "ADC"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "4086"
    },
    {
      "row_id": "ROW_4088",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_4107",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_4132",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1699eP",
      "regimen": "encorafenib plus binimetinib",
      "drugs": [
        "encorafenib",
        "binimetinib"
      ],
      "biomarkers": [],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "720eP",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_4158",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "34eP",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "173TiP",
      "regimen": "Circulating tumour DNA guided Adaptive BRAF and MEK Inhibitor therapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Phase 2",
      "trial_id": "DyNAMIc"
    },
    {
      "row_id": "276eP",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_4250",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "218eP",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "9P",
      "regimen": "amivantamab",
      "drugs": [
        "amivantamab"
      ],
      "biomarkers": [
        "MET"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "124P",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_4302",
      "regimen": "",
      "drugs": [],
      "biomarkers": [
        "KRAS"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "3002P",
      "regimen": "Dabrafenib Plus Trametinib",
      "drugs": [
        "Dabrafenib",
        "Trametinib"
      ],
      "biomarkers": [],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1654P",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2998P",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_4384",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1784eP",
      "regimen": "salivary exosome-based liquid biopsy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1514O",
      "regimen": "TCR-T therapy targeting KRAS G12V",
      "drugs": [],
      "biomarkers": [
        "KRAS G12V",
        "KRAS"
      ],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 1",
      "trial_id": ""
    },
    {
      "row_id": "926MO",
      "regimen": "MK-1084 Monotherapy",
      "drugs": [
        "MK-1084"
      ],
      "biomarkers": [
        "KRAS G12C",
        "KRAS"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 1",
      "trial_id": "KANDLELIT-001"
    },
    {
      "row_id": "927MO",
      "regimen": "single-agent divarasib",
      "drugs": [
        "divarasib"
      ],
      "biomarkers": [
        "KRAS G12C",
        "KRAS"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "927MO"
    },
    {
      "row_id": "ROW_163",
      "regimen": "c-Met protein directed strategies",
      "drugs": [],
      "biomarkers": [
        "c-Met"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_163"
    },
    {
      "row_id": "2022P",
      "regimen": "immunotherapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2022P"
    },
    {
      "row_id": "2650P",
      "regimen": "metastasis-directed therapies",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2650P"
    },
    {
      "row_id": "1918P",
      "regimen": "evaluation of a GPT-based conversational AI tool",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Other"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1918P"
    },
    {
      "row_id": "1921P",
      "regimen": "computational modeling for rare mutations",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Other"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1921P"
    },
    {
      "row_id": "1798P",
      "regimen": "molecular landscape prediction",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Other"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1798P"
    },
    {
      "row_id": "1808eP",
      "regimen": "bronchoalveolar lavage",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Other"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1808eP"
    },
    {
      "row_id": "2013P",
      "regimen": "repotrectinib",
      "drugs": [
        "repotrectinib"
      ],
      "biomarkers": [
        "NTRK"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2013P"
    },
    {
      "row_id": "1815eP",
      "regimen": "Aumolertinib",
      "drugs": [
        "Aumolertinib"
      ],
      "biomarkers": [
        "EGFR"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "1815eP"
    },
    {
      "row_id": "LBA33",
      "regimen": "ctDNA-Guided Anti-EGFR Rechallenge",
      "drugs": [
        "Anti-EGFR"
      ],
      "biomarkers": [
        "ctDNA"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Phase 2",
      "trial_id": "CITRIC"
    },
    {
      "row_id": "1940P",
      "regimen": "Cerebrospinal Fluid cfDNA Analysis",
      "drugs": [],
      "biomarkers": [
        "cfDNA"
      ],
      "modality": [
        "Other"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1940P"
    },
    {
      "row_id": "1833P",
      "regimen": "Multi-marker methylation panel (epiLung)",
      "drugs": [],
      "biomarkers": [
        "methylation markers"
      ],
      "modality": [
        "Other"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1833P"
    },
    {
      "row_id": "2045eP",
      "regimen": "Perivascular Spaces as Immune Gatekeepers",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Other"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2045eP"
    },
    {
      "row_id": "1797P",
      "regimen": "Clinical risk stratification",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Other"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1797P"
    },
    {
      "row_id": "ROW_455",
      "regimen": "Evolving treatment strategies",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Other"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_455"
    },
    {
      "row_id": "ROW_500",
      "regimen": "Targeting KRAS",
      "drugs": [],
      "biomarkers": [
        "KRAS"
      ],
      "modality": [
        "Other"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_500"
    },
    {
      "row_id": "1914P",
      "regimen": "Sex differences in tolerability to Targeted Therapies",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Other"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1914P"
    },
    {
      "row_id": "ROW_519",
      "regimen": "Invited Discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Other"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_519"
    },
    {
      "row_id": "2535eP",
      "regimen": "PSMA-PET CT scans for prostate cancer staging and surveillance",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_572",
      "regimen": "anti-EGFR rechallenge",
      "drugs": [
        "anti-EGFR"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "3201eP",
      "regimen": "earlier detection of lung cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_589",
      "regimen": "BRAF mt mCRC",
      "drugs": [],
      "biomarkers": [
        "BRAF"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_613",
      "regimen": "small things matter",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_901",
      "regimen": "State-of-the-art in 2025",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "LBA32",
      "regimen": "Panitumumab retreatment followed by regorafenib",
      "drugs": [
        "Panitumumab",
        "regorafenib"
      ],
      "biomarkers": [
        "RAS",
        "BRAF"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2080eTiP",
      "regimen": "iza-bren (BL-B01D1) combinations",
      "drugs": [
        "iza-bren",
        "BL-B01D1"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Phase 1",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1111",
      "regimen": "long-term patient-centred care",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1112",
      "regimen": "long-term patient-centred care",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1113",
      "regimen": "Summary and close",
      "trial_id": "ROW_1113",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_1155",
      "regimen": "New targets",
      "trial_id": "ROW_1155",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_1809",
      "regimen": "Optimising patient supportive care",
      "trial_id": "ROW_1809",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_1829",
      "regimen": "Advances in first-line strategies",
      "trial_id": "ROW_1829",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_1994",
      "regimen": "Invited Discussant",
      "trial_id": "ROW_1994",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_2005",
      "regimen": "Lung cancer care: Implementing shared decision-making",
      "trial_id": "ROW_2005",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_2006",
      "regimen": "Discussion",
      "trial_id": "ROW_2006",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_2031",
      "regimen": "Invited Discussant",
      "trial_id": "ROW_2031",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_2067",
      "regimen": "How to define an unfit population",
      "trial_id": "ROW_2067",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_2099",
      "regimen": "Invited Discussant",
      "trial_id": "ROW_2099",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "891eP",
      "regimen": "anti-BRAF and anti-EGFR therapy",
      "drugs": [
        "anti-BRAF",
        "anti-EGFR"
      ],
      "biomarkers": [
        "BRAF V600E"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "LBA35",
      "regimen": "Iza-Bren (BL-B01D1) versus Physician's Choice of Chemotherapy",
      "drugs": [
        "Iza-Bren (BL-B01D1)",
        "Chemotherapy"
      ],
      "biomarkers": [
        "EGFR",
        "HER3"
      ],
      "modality": [
        "ADC",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "727MO",
      "regimen": "FOLFOX plus PANITUMUMAB according to a 'stop-and-go' strategy",
      "drugs": [
        "FOLFOX",
        "PANITUMUMAB"
      ],
      "biomarkers": [
        "RAS",
        "BRAF"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "931P",
      "regimen": "necitumumab",
      "drugs": [
        "necitumumab"
      ],
      "biomarkers": [
        "EGFR"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "WJOG15021M"
    },
    {
      "row_id": "855P",
      "regimen": "Larotrectinib",
      "drugs": [
        "Larotrectinib"
      ],
      "biomarkers": [
        "NTRK"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "933P",
      "regimen": "iza-bren (BL-B01D1)",
      "drugs": [
        "iza-bren (BL-B01D1)"
      ],
      "modality": [
        "ADC"
      ],
      "population": "Other",
      "phase": "Phase 1",
      "trial_id": "933P",
      "biomarkers": []
    },
    {
      "row_id": "1575P",
      "regimen": "Tocilizumab",
      "drugs": [
        "Tocilizumab"
      ],
      "population": "Other",
      "phase": "Phase 2",
      "trial_id": "1575P",
      "biomarkers": []
    },
    {
      "row_id": "918O",
      "regimen": "telisotuzumab adizutecan (ABBV-400; Temab-A)",
      "drugs": [
        "telisotuzumab adizutecan (ABBV-400; Temab-A)"
      ],
      "population": "Other",
      "phase": "Phase 1",
      "trial_id": "918O",
      "biomarkers": []
    },
    {
      "row_id": "839P",
      "regimen": "Encorafenib, cetuximab, plus binimetinib",
      "drugs": [
        "Encorafenib",
        "cetuximab",
        "binimetinib"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "839P",
      "biomarkers": []
    },
    {
      "row_id": "738P",
      "regimen": "pertuzumab plus trastuzumab",
      "drugs": [
        "pertuzumab",
        "trastuzumab"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "738P",
      "biomarkers": [
        "HER2"
      ]
    },
    {
      "row_id": "846P",
      "regimen": "Anti-EGFR Monoclonal Antibodies",
      "drugs": [
        "Anti-EGFR Monoclonal Antibodies"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "846P",
      "biomarkers": [
        "PIK3CA"
      ]
    },
    {
      "row_id": "2240P",
      "regimen": "Major KRAS Variants",
      "drugs": [],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "2240P",
      "biomarkers": [
        "KRAS"
      ]
    },
    {
      "row_id": "800P",
      "regimen": "mCapOX plus cetuximab with mFOLFOX6 plus cetuximab",
      "drugs": [
        "mCapOX",
        "cetuximab",
        "mFOLFOX6"
      ],
      "population": "Other",
      "phase": "Phase 2",
      "trial_id": "800P",
      "biomarkers": []
    },
    {
      "row_id": "2129P",
      "regimen": "Transarterial infusion chemotherapy and embolization (TAICE)",
      "drugs": [],
      "population": "Other",
      "phase": "Phase 2",
      "trial_id": "2129P",
      "biomarkers": []
    },
    {
      "row_id": "2996P",
      "regimen": "Radioactive Iodine-Refractory Differentiated Thyroid Cancer treatment",
      "drugs": [
        "BRAF Mutation"
      ],
      "biomarkers": [
        "BRAF"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2996P"
    },
    {
      "row_id": "265eP",
      "regimen": "Flow SuperRCA for KRAS Mutation Detection",
      "drugs": [
        "KRAS Mutation"
      ],
      "biomarkers": [
        "KRAS"
      ],
      "modality": [
        "Not specified"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "265eP"
    },
    {
      "row_id": "36eP",
      "regimen": "NCOA4 as an immunological and prognostic biomarker",
      "drugs": [],
      "biomarkers": [
        "NCOA4"
      ],
      "modality": [
        "Not specified"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "36eP"
    },
    {
      "row_id": "3046eP",
      "regimen": "Co-Mutational Racial Disparities in EGFR positive Lung Cancer",
      "drugs": [],
      "biomarkers": [
        "EGFR"
      ],
      "modality": [
        "Not specified"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "3046eP"
    },
    {
      "row_id": "ROW_3217",
      "regimen": "Germline mutations testing",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Not specified"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_3217"
    },
    {
      "row_id": "1786O",
      "regimen": "AI for early-stage lung cancer recurrence prognosis",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Not specified"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1786O"
    },
    {
      "row_id": "1682P",
      "regimen": "BRAF plus MEK inhibitors treatment",
      "drugs": [
        "BRAF",
        "MEK inhibitors"
      ],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "1682P"
    },
    {
      "row_id": "1753eP",
      "regimen": "Microdose Trial of [68Ga]Ga-R54",
      "drugs": [
        "[68Ga]Ga-R54"
      ],
      "biomarkers": [],
      "modality": [
        "Not specified"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1753eP"
    },
    {
      "row_id": "171P",
      "regimen": "NTRK+ solid tumors treatment",
      "drugs": [],
      "biomarkers": [
        "NTRK"
      ],
      "modality": [
        "Not specified"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "171P"
    },
    {
      "row_id": "3029eP",
      "regimen": "KRAS G12C inhibitors treatment",
      "drugs": [
        "KRAS G12C inhibitors"
      ],
      "biomarkers": [
        "ASS1",
        "EGFR",
        "KRAS"
      ],
      "modality": [
        "Not specified"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "3029eP"
    },
    {
      "row_id": "249eP",
      "regimen": "systematic review and meta-analysis",
      "drugs": [],
      "biomarkers": [
        "EGFR"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "687P",
      "regimen": "Targeted therapy",
      "drugs": [],
      "biomarkers": [
        "BRAF",
        "NTRK"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1646P",
      "regimen": "second-line BRAF/MEK inhibitors",
      "drugs": [
        "BRAF",
        "MEK"
      ],
      "biomarkers": [
        "BRAFV600"
      ],
      "modality": [],
      "population": "Other",
      "line": "2L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "16P",
      "regimen": "TET2-Mutant Clonal Hematopoiesis",
      "drugs": [],
      "biomarkers": [
        "TET2"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1721P",
      "regimen": "External validation of Rachel score",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2991P",
      "regimen": "anlotinib plus sintilimab",
      "drugs": [
        "anlotinib",
        "sintilimab"
      ],
      "biomarkers": [
        "BRAF"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "68eP",
      "regimen": "promotes lung metastasis",
      "drugs": [],
      "biomarkers": [
        "GPX3"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "18P",
      "regimen": "Clinical Efficacy and Immune Mechanism of PD-1/CTLA-4 Bispecific Antibody Cadonilimab",
      "drugs": [
        "Cadonilimab"
      ],
      "biomarkers": [],
      "modality": [
        "Bispecific"
      ],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1643P",
      "regimen": "regorafenib combined with BRAF-/MEK-inhibitors",
      "drugs": [
        "regorafenib",
        "BRAF-inhibitors",
        "MEK-inhibitors"
      ],
      "biomarkers": [
        "BRAFV600"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "RegoMel"
    },
    {
      "row_id": "2214MO",
      "regimen": "telisotuzumab adizutecan",
      "drugs": [
        "telisotuzumab adizutecan",
        "ABBV-400",
        "Temab-A"
      ],
      "biomarkers": [
        "c-Met"
      ],
      "modality": [
        "ADC"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": "2214MO"
    },
    {
      "row_id": "1645P",
      "regimen": "Combination of Encorafenib, Binimetinib and Palbociclib",
      "drugs": [
        "Encorafenib",
        "Binimetinib",
        "Palbociclib"
      ],
      "biomarkers": [
        "BRAF-Mutant"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1b",
      "trial_id": "1645P"
    },
    {
      "row_id": "1694eP",
      "regimen": "induction targeted therapy with immune checkpoint inhibitor therapy switch",
      "drugs": [
        "BRAF",
        "ICI"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "1694eP",
      "biomarkers": []
    },
    {
      "row_id": "196eP",
      "regimen": "SOS1 inhibitor and EGFR inhibitor combinations",
      "drugs": [
        "BMS-986509",
        "adagrasib"
      ],
      "biomarkers": [
        "KRAS G12C",
        "KRAS"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "196eP"
    },
    {
      "row_id": "1623P",
      "regimen": "switching from BRAF/MEK inhibition to immune checkpoint inhibition",
      "drugs": [
        "BRAF",
        "MEK",
        "ICI"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1623P",
      "biomarkers": []
    },
    {
      "row_id": "1647P",
      "regimen": "Dabrafenib/trametinib versus encorafenib/binimetinib",
      "drugs": [
        "Dabrafenib",
        "Trametinib",
        "Encorafenib",
        "Binimetinib"
      ],
      "biomarkers": [
        "BRAF"
      ],
      "modality": [
        "TKI"
      ],
      "population": "mUC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "1647P"
    },
    {
      "row_id": "683P",
      "regimen": "Dual Immune Checkpoint Inhibition",
      "drugs": [
        "BRAF",
        "NRAS",
        "PD-L1",
        "C-KIT"
      ],
      "biomarkers": [
        "BRAF",
        "NRAS",
        "PD-L1",
        "C-KIT"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "683P"
    },
    {
      "row_id": "ROW_4650",
      "trial_id": "ROW_4650",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_4655",
      "trial_id": "ROW_4655",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_4671",
      "modality": [
        "IO"
      ],
      "trial_id": "ROW_4671",
      "drugs": [],
      "biomarkers": []
    }
  ],
  "colorectal_cancer": [
    {
      "row_id": "LBA33",
      "regimen": "ctDNA-guided anti-EGFR rechallenge strategy",
      "drugs": [
        "EGFR",
        "ctDNA"
      ],
      "biomarkers": [
        "RAS",
        "BRAF"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Phase 2",
      "trial_id": "CITRIC"
    },
    {
      "row_id": "LBA32",
      "regimen": "Panitumumab retreatment followed by regorafenib",
      "drugs": [
        "Panitumumab",
        "Regorafenib"
      ],
      "biomarkers": [
        "RAS",
        "BRAF"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "723O",
      "regimen": "liquid biopsy-guided treatment",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Phase 2",
      "trial_id": "PEGASUS"
    },
    {
      "row_id": "775P",
      "regimen": "Neoadjuvant Chemotherapy and Short Course Radiation Therapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Chemotherapy",
        "Radiotherapy"
      ],
      "population": "MIBC",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "SPADE"
    },
    {
      "row_id": "1018eTiP",
      "regimen": "Oral MYB Transcription Factor Inhibitor",
      "drugs": [
        "RGT-61159"
      ],
      "biomarkers": [],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1486",
      "regimen": "improve drug development",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1213",
      "regimen": "biomarker analysis and molecular subtyping",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_823",
      "regimen": "Optimizing Treatment Options",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1158",
      "regimen": "liquid biopsy in CRC",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_509",
      "regimen": "RAS/RAF blockade",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_88",
      "regimen": "MSI-H/dMMR CRC",
      "drugs": [],
      "biomarkers": [
        "MSI",
        "dMMR"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_94",
      "regimen": "BMS Therapeutic Pipeline",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1MO",
      "regimen": "Placental features overexpression",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "724O",
      "regimen": "comparison of outcomes in clinical trials",
      "drugs": [],
      "biomarkers": [
        "dMMR"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "CN42",
      "regimen": "Screening Adherence Drives Cost-Effectiveness",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "745P",
      "regimen": "secondary resection of metastases",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2323P",
      "regimen": "non-OS endpoints",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1744",
      "regimen": "Cell proliferation and DNA repair defects",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "769P",
      "regimen": "Liquid Biopsy in Stage II Colon Cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "853P",
      "regimen": "anti-EGFR resistance mutations in RAS/BRAF-wild type left-sided metastatic colorectal cancer",
      "drugs": [
        "cetuximab"
      ],
      "biomarkers": [
        "RAS",
        "BRAF"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 3",
      "trial_id": "CRC01"
    },
    {
      "row_id": "892eP",
      "regimen": "Emerging trends of early-onset colorectal cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "740P",
      "regimen": "Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC)",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "HIPECT4"
    },
    {
      "row_id": "2942eP",
      "regimen": "incidence of cardiotoxicity in the treatment of colorectal cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "810P",
      "regimen": "Multimodal Treatment on Sexual Function in Patients with Rectal Cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "787P",
      "regimen": "organ preservation approach in patients with locally advanced rectal cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "CHORD"
    },
    {
      "row_id": "886eP",
      "regimen": "impact of RAS and BRAF mutations on immunotherapy outcomes",
      "drugs": [],
      "biomarkers": [
        "RAS",
        "BRAF",
        "MSI",
        "dMMR"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "848P",
      "regimen": "Treatment pathways and efficacy outcomes of patients with metastatic colorectal cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "mCRC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "PROMETCO"
    },
    {
      "row_id": "885eP",
      "regimen": "Hepatic arterial infusion chemotherapy (HAIC) as intensification or salvage treatment",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "mCRC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2882P",
      "regimen": "Malignant Bowel Obstruction in Advanced Cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "782P",
      "regimen": "Neoadjuvant therapy for Locally Advanced Rectal Cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "840P",
      "regimen": "Circulating Biomarkers in Primary and Metastatic Colorectal Cancer Patients",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "821P",
      "regimen": "Functional precision medicine using MicroOrganoSpheres",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "850P",
      "regimen": "Short-term fasting vs. individualized nutrition during chemotherapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "901eP",
      "regimen": "Tertiary lymphoid structures (TLSs) in metastatic colorectal cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "mCRC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "811P",
      "regimen": "Safety and tolerability of fruquintinib",
      "drugs": [
        "fruquintinib"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "mCRC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1932",
      "regimen": "Immunotherapy in MSS/pMMR colorectal cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "878eP",
      "regimen": "impact of a novel liquid biopsy blood test on PROMs and PREMs",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1",
      "regimen": "Anti-EGFR Monoclonal Antibodies",
      "drugs": [
        "Anti-EGFR Monoclonal Antibodies"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "846P",
      "biomarkers": []
    },
    {
      "row_id": "2",
      "regimen": "mCapOX plus cetuximab",
      "drugs": [
        "mCapOX",
        "cetuximab",
        "mFOLFOX6"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": "800P",
      "biomarkers": []
    },
    {
      "row_id": "3",
      "regimen": "sirexatamab plus bevacizumab and chemotherapy",
      "drugs": [
        "sirexatamab",
        "bevacizumab",
        "chemotherapy"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Phase 2",
      "trial_id": "LBA34",
      "biomarkers": []
    },
    {
      "row_id": "4",
      "regimen": "Zanzalintinib plus atezolizumab",
      "drugs": [
        "Zanzalintinib",
        "atezolizumab",
        "regorafenib"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Not specified",
      "trial_id": "LBA30",
      "biomarkers": []
    },
    {
      "row_id": "5",
      "regimen": "Not specified",
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "842P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "6",
      "regimen": "Conversion Surgery",
      "population": "mCRC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "827P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "7",
      "regimen": "Not specified",
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "734MO",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "8",
      "regimen": "panitumumab vs bevacizumab",
      "drugs": [
        "panitumumab",
        "bevacizumab"
      ],
      "population": "mCRC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "826P",
      "biomarkers": []
    },
    {
      "row_id": "9",
      "regimen": "Encorafenib + cetuximab + binimetinib",
      "drugs": [
        "Encorafenib",
        "cetuximab",
        "binimetinib"
      ],
      "population": "mCRC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "839P",
      "biomarkers": []
    },
    {
      "row_id": "10",
      "regimen": "pertuzumab + trastuzumab",
      "drugs": [
        "pertuzumab",
        "trastuzumab"
      ],
      "population": "mCRC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "738P",
      "biomarkers": []
    },
    {
      "row_id": "11",
      "regimen": "A Multicenter-Derived Nodal Classification System for Colon Cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "820P"
    },
    {
      "row_id": "12",
      "regimen": "sirexatamab plus bevacizumab and chemotherapy versus bevacizumab and chemotherapy",
      "drugs": [
        "sirexatamab",
        "bevacizumab"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "2L",
      "phase": "Phase 2",
      "trial_id": "LBA34"
    },
    {
      "row_id": "13",
      "regimen": "Utilizing circulating tumor DNA methylation as postoperative surveillance for colorectal cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "765P"
    },
    {
      "row_id": "14",
      "regimen": "Zanzalintinib plus atezolizumab vs regorafenib in previously treated metastatic colorectal cancer",
      "drugs": [
        "zanzalintinib",
        "atezolizumab",
        "regorafenib"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "mCRC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "LBA30"
    },
    {
      "row_id": "15",
      "regimen": "Diagnostic Accuracy of Circulating Tumor DNA-Based Liquid Biopsy for Colorectal Cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1743P"
    },
    {
      "row_id": "16",
      "regimen": "Towards achieving full MSI reflex testing in CRC, GC and EC",
      "drugs": [],
      "biomarkers": [
        "MSI"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1756eP"
    },
    {
      "row_id": "17",
      "regimen": "Real-World Characteristics and Outcomes",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "mCRC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "873eP"
    },
    {
      "row_id": "18",
      "regimen": "SSGJ-707 targeting PD-1 and VEGF with chemotherapy",
      "drugs": [
        "SSGJ-707"
      ],
      "biomarkers": [
        "PD-1",
        "VEGF"
      ],
      "modality": [
        "Bispecific",
        "Chemotherapy"
      ],
      "population": "mCRC",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "796P"
    },
    {
      "row_id": "19",
      "regimen": "immunotherapy impact on mCRC",
      "drugs": [],
      "biomarkers": [
        "mismatch repair"
      ],
      "modality": [
        "IO"
      ],
      "population": "mCRC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "900eP"
    },
    {
      "row_id": "20",
      "regimen": "Short-course Radiotherapy followed by Chemotherapy and PD-L1 inhibitor",
      "drugs": [],
      "biomarkers": [
        "PD-L1"
      ],
      "modality": [
        "Radiotherapy",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "779P"
    },
    {
      "row_id": "739P",
      "regimen": "microsatellite instability detection",
      "drugs": [],
      "biomarkers": [
        "MSI"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "739P"
    },
    {
      "row_id": "2959eP",
      "regimen": "EGFR-targeted monoclonal antibodies",
      "drugs": [
        "EGFR-targeted monoclonal antibodies"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2959eP"
    },
    {
      "row_id": "891eP",
      "regimen": "anti-BRAF and anti-EGFR therapy",
      "drugs": [
        "anti-BRAF",
        "anti-EGFR"
      ],
      "biomarkers": [
        "BRAF V600E"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "891eP"
    },
    {
      "row_id": "802P",
      "regimen": "immunotherapy with pembrolizumab",
      "drugs": [
        "pembrolizumab"
      ],
      "biomarkers": [
        "MSI-H",
        "MSI"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "802P"
    },
    {
      "row_id": "752P",
      "regimen": "randomized trial of adjuvant therapy",
      "drugs": [
        "atezolizumab"
      ],
      "biomarkers": [
        "dMMR",
        "PD-L1"
      ],
      "modality": [],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Not specified",
      "trial_id": "752P"
    },
    {
      "row_id": "834P",
      "regimen": "AI-Driven Colorectal Cancer Risk Stratification",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "834P"
    },
    {
      "row_id": "2881P",
      "regimen": "Total Neoadjuvant Therapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "2881P"
    },
    {
      "row_id": "2365P",
      "regimen": "Community-based Survivorship Care",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2365P"
    },
    {
      "row_id": "797P",
      "regimen": "Irinotecan Liposome combined with 5-FU/LV and Bevacizumab",
      "drugs": [
        "Irinotecan Liposome",
        "5-FU",
        "LV",
        "Bevacizumab"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "2L",
      "phase": "Phase 2",
      "trial_id": "797P"
    },
    {
      "row_id": "763P",
      "regimen": "blood-based multiplex methylation assay",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "763P"
    },
    {
      "row_id": "907eTiP",
      "regimen": "fecal microbiota transplantation plus QL1706 plus Bevacizumab plus XELOX",
      "drugs": [
        "QL1706",
        "Bevacizumab",
        "XELOX"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": "907eTiP"
    },
    {
      "row_id": "864eP",
      "regimen": "second recurrence after resection",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "864eP"
    },
    {
      "row_id": "841P",
      "regimen": "dose-escalation study evaluating ginisortamab",
      "drugs": [
        "ginisortamab",
        "5-fluorouracil"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1/2",
      "trial_id": "841P"
    },
    {
      "row_id": "777P",
      "regimen": "chemoradiotherapy followed by immune checkpoint blockade",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "777P"
    },
    {
      "row_id": "803P",
      "regimen": "Neo BRAF wild-type metastatic colorectal cancer",
      "drugs": [],
      "biomarkers": [
        "BRAF wild-type"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "803P"
    },
    {
      "row_id": "2964eP",
      "regimen": "serum substance P level prediction",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2964eP"
    },
    {
      "row_id": "762P",
      "regimen": "incident colorectal cancer associated with smoking",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "762P"
    },
    {
      "row_id": "760P",
      "regimen": "incidence of primary colorectal cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "760P"
    },
    {
      "row_id": "852P",
      "regimen": "Neoadjuvant Options in Synchronous mCRC",
      "drugs": [],
      "biomarkers": [
        "RAS mutated",
        "RAS wild type"
      ],
      "modality": [],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "852P"
    },
    {
      "row_id": "785P",
      "regimen": "Neoadjuvant Chemotherapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "785P"
    },
    {
      "row_id": "870eP",
      "regimen": "local radical therapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "870eP"
    },
    {
      "row_id": "880eP",
      "regimen": "Encorafenib + Cetuximab",
      "drugs": [
        "Encorafenib",
        "Cetuximab"
      ],
      "biomarkers": [
        "BRAF V600E"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "880eP"
    },
    {
      "row_id": "890eP",
      "regimen": "Trifluridine-Tipiracil with or without Bevacizumab",
      "drugs": [
        "Trifluridine-Tipiracil",
        "Bevacizumab"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "890eP"
    },
    {
      "row_id": "814P",
      "regimen": "anti-EGFR therapy",
      "drugs": [],
      "biomarkers": [
        "RAS",
        "BRAF V600E"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "814P"
    },
    {
      "row_id": "793P",
      "regimen": "induction chemotherapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "793P"
    },
    {
      "row_id": "792P",
      "regimen": "Frontline Anti-VEGF and Anti-EGFR Exposure",
      "drugs": [
        "Trifluridine/Tipiracil",
        "Bevacizumab",
        "Regorafenib"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "792P"
    },
    {
      "row_id": "851P",
      "regimen": "Botensilimab, Balstilimab and Regorafenib",
      "drugs": [
        "Botensilimab",
        "Balstilimab",
        "Regorafenib"
      ],
      "biomarkers": [
        "MSS"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": "851P"
    },
    {
      "row_id": "869eP",
      "regimen": "Incidence of Colorectal Cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "869eP"
    },
    {
      "row_id": "764P",
      "regimen": "tumor-informed molecular residual disease detection",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "764P"
    },
    {
      "row_id": "776P",
      "regimen": "predictive factors for severe toxicities",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "776P"
    },
    {
      "row_id": "1597eTiP",
      "regimen": "Personalised Tumour Trained Lymphocytes",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase I/IIa",
      "trial_id": "1597eTiP"
    },
    {
      "row_id": "2197P",
      "regimen": "Return to Work After Curative Cancer Treatment",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2197P"
    },
    {
      "row_id": "899eP",
      "regimen": "Individualized Triplet Chemotherapy Decision-Making",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "899eP"
    },
    {
      "row_id": "784P",
      "regimen": "prediction of metastatic lymph nodes",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "784P"
    },
    {
      "row_id": "731MO",
      "regimen": "Telisotuzumab adizutecan + Bevacizumab vs SOC",
      "drugs": [
        "Telisotuzumab adizutecan",
        "Bevacizumab"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "3L",
      "phase": "Not specified",
      "trial_id": "731MO"
    },
    {
      "row_id": "909eTiP",
      "regimen": "AMB-05X for ctDNA(+) colorectal cancer",
      "drugs": [
        "AMB-05X"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "909eTiP"
    },
    {
      "row_id": "766P",
      "regimen": "tissue-agnostic approach for detecting MRD",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "766P"
    },
    {
      "row_id": "808P",
      "regimen": "Tumor Microenvironment Heterogeneity and Resistance Mechanisms to HER2 Inhibition",
      "drugs": [],
      "biomarkers": [
        "HER2"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "808P"
    },
    {
      "row_id": "795P",
      "regimen": "Optimizing Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "795P"
    },
    {
      "row_id": "744P",
      "regimen": "Validating ARCAD-Derived External Control Arms",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "744P"
    },
    {
      "row_id": "868eP",
      "regimen": "Robotic-Assisted, Laparoscopic and Open Surgery",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "832P",
      "regimen": "First-line Metastatic Colorectal Cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "PLATFORM-B"
    },
    {
      "row_id": "902eTiP",
      "regimen": "DPD phenotype-guided dose individualization of fluoropyrimidine-based chemotherapy",
      "drugs": [
        "fluoropyrimidine"
      ],
      "biomarkers": [
        "DPD"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "730MO",
      "regimen": "Trifluridine/Tipiracil with Capecitabine and Bevacizumab",
      "drugs": [
        "Trifluridine",
        "Tipiracil",
        "Capecitabine",
        "Bevacizumab"
      ],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": "TriComB"
    },
    {
      "row_id": "790P",
      "regimen": "Induction chemotherapy with mDCF prior to Chemoradiotherapy",
      "drugs": [
        "mDCF"
      ],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "761P",
      "regimen": "Early-Onset Colorectal Cancer Study",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "898eP",
      "regimen": "Fruquintinib alternating with Bevacizumab plus Capecitabine",
      "drugs": [
        "Fruquintinib",
        "Bevacizumab",
        "Capecitabine"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Maintenance",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "2334P",
      "regimen": "Socioeconomic Status and Overall Survival in Colorectal Cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "911eTiP",
      "regimen": "Node-sparing modified Short-Course Radiation with CAPOX and Sintilimab",
      "drugs": [
        "CAPOX",
        "Sintilimab"
      ],
      "biomarkers": [],
      "modality": [
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "836P",
      "regimen": "Immunotherapy-Based Total Neoadjuvant Therapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "887eP",
      "regimen": "SBRT Combined with Immune Checkpoint Inhibitors",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "894eP",
      "regimen": "Global Disease Burden of Colorectal Cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "733P",
      "regimen": "Atezolizumab with or without Tiragolumab following neoadjuvant chemoradiotherapy",
      "drugs": [
        "Atezolizumab",
        "Tiragolumab",
        "atezolizumab"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "NEOTE"
    },
    {
      "row_id": "741P",
      "regimen": "Chemoradiotherapy followed by tislelizumab and CAPOX",
      "drugs": [
        "tislelizumab",
        "CAPOX"
      ],
      "biomarkers": [],
      "modality": [
        "Chemotherapy",
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "RELIEVE-01"
    },
    {
      "row_id": "877eP",
      "regimen": "Non‐Alcoholic Fatty Liver Disease and Risk of Early-Onset Colorectal Cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "863eP",
      "regimen": "Impact of Inflammatory Status on Quality of Life in Advanced Colorectal Cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "905eTiP",
      "regimen": "CAPOX plus PD-1 inhibitor with or without short-course radiotherapy",
      "drugs": [
        "CAPOX",
        "PD-1 inhibitor"
      ],
      "biomarkers": [],
      "modality": [
        "Chemotherapy",
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "TORCH-iTNT"
    },
    {
      "row_id": "783P",
      "regimen": "Neoadjuvant envafolimab combined with chemoradiotherapy",
      "drugs": [
        "envafolimab"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "Not specified"
    },
    {
      "row_id": "LBA31",
      "regimen": "Neoadjuvant immunotherapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "754P",
      "regimen": "Predicting sex-specific subsequent primary extracolonic cancer risks",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "ROW_3432",
      "regimen": "Current treatment strategies",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "3065eP",
      "regimen": "HLA loss of heterozygosity in colorectal cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_3544",
      "regimen": "Early CRC Treatment",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_3585",
      "regimen": "Multidisciplinary treatment approaches",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "6P",
      "regimen": "Patient-Derived Organoid Assays",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1764eP",
      "regimen": "Multi-omic liquid biopsy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "LBA9",
      "regimen": "ctDNA-Guided Adjuvant Chemotherapy De-Escalation",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Phase 3",
      "trial_id": "AGITG DYNAMIC-III"
    },
    {
      "row_id": "287eP",
      "regimen": "Comprehensive genomic profiling",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "32eP",
      "regimen": "Exosomal miR-382-5p inhibits pre-metastatic niche formation",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "726O",
      "regimen": "Combined Analysis of Pathologists and AI",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_3962",
      "regimen": "Positioning later line treatment options",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1772eP",
      "regimen": "Blood-only, Targeted Methylation ctDNA Assay",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "156P",
      "regimen": "FOLFOXIRI/bevacizumab combined with nivolumab",
      "drugs": [
        "FOLFOXIRI",
        "bevacizumab",
        "nivolumab"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "mCRC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1736eP",
      "regimen": "Treatment Sequence in Advanced Small Bowel Neuroendocrine Neoplasms",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "251eP",
      "regimen": "Integrative cfDNA Fragmentation and Methylation Profiling",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "7P",
      "regimen": "Spatial single-cell imaging and transcriptomic profiling",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "670P",
      "regimen": "Intra-CSF delivery of Dual CD19/CD22 CAR-T Therapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "CAR-T"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_4196",
      "regimen": "Time to address liver transplantation",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "mCRC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "LBA29",
      "regimen": "Nivolumab plus ipilimumab vs nivolumab monotherapy",
      "drugs": [
        "nivolumab",
        "ipilimumab"
      ],
      "biomarkers": [
        "MSI",
        "dMMR"
      ],
      "modality": [],
      "population": "mCRC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_4300",
      "regimen": "Introduction and welcome",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_4301",
      "regimen": "Immunotherapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_4302",
      "regimen": "Targeting KRAS and TGFbeta",
      "drugs": [],
      "biomarkers": [
        "KRAS",
        "TGFbeta"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_4330",
      "regimen": "Nursing management of side effects",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "266eP",
      "regimen": "Nelmastobart plus Capecitabine",
      "drugs": [
        "Nelmastobart",
        "Capecitabine"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Phase Ib/II",
      "phase": "Phase 1",
      "trial_id": "266eP"
    },
    {
      "row_id": "ROW_4422",
      "regimen": "Supporting adherence and monitoring",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "56eP",
      "regimen": "Targeting the RMI2-RAD51 Axis",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "56eP"
    },
    {
      "row_id": "143P",
      "regimen": "Spatial Heterogeneity of the Immune Microenvironment",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "143P"
    },
    {
      "row_id": "ROW_4660",
      "regimen": "Refining patient selection for regional therapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_4661",
      "regimen": "Discussion",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "881eP",
      "regimen": "neoadjuvant chemoradiotherapy (nCRT) combined with camrelizumab",
      "drugs": [
        "camrelizumab"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "EV-302",
      "biomarkers": []
    },
    {
      "row_id": "858P",
      "regimen": "Exploring antigen presentation and Wnt/beta-Catenin pathway alterations",
      "drugs": [],
      "biomarkers": [
        "Microsatellite",
        "MSI"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "889eP",
      "regimen": "adjuvant treatment",
      "drugs": [],
      "modality": [],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Not specified",
      "trial_id": "",
      "biomarkers": []
    },
    {
      "row_id": "849P",
      "regimen": "Pro-inflammatory Immune Cell Infiltration",
      "drugs": [],
      "biomarkers": [
        "Consensus Molecular Subtype"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "806P",
      "regimen": "biparatopic anti-HER2 antibody conjugate (ADC)",
      "drugs": [
        "JSKN003"
      ],
      "modality": [
        "ADC"
      ],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": "",
      "biomarkers": [
        "HER2"
      ]
    },
    {
      "row_id": "845P",
      "regimen": "Liposomal irinotecan combined with capecitabine and bevacizumab",
      "drugs": [
        "liposomal irinotecan",
        "capecitabine",
        "bevacizumab"
      ],
      "modality": [],
      "population": "Other",
      "line": "2L",
      "phase": "Not specified",
      "trial_id": "",
      "biomarkers": []
    },
    {
      "row_id": "882eP",
      "regimen": "Intratumoural IVX037",
      "drugs": [
        "IVX037"
      ],
      "biomarkers": [
        "CD55",
        "KRAS"
      ],
      "modality": [
        "Vaccine"
      ],
      "population": "Other",
      "line": "",
      "phase": "Phase 1",
      "trial_id": ""
    },
    {
      "row_id": "833P",
      "regimen": "Real-World Survival Outcomes Stratified by Oncogene Expression",
      "drugs": [],
      "biomarkers": [
        "Oncogene Expression"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "801P",
      "regimen": "Prognostic and Predictive Value of ctDNA-MSI",
      "drugs": [],
      "biomarkers": [
        "ctDNA",
        "MSI"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "838P",
      "regimen": "ginisortamab (UCB6114) with trifluridine/tipir",
      "drugs": [
        "ginisortamab",
        "trifluridine",
        "tipir"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Phase 1/2",
      "trial_id": ""
    },
    {
      "row_id": "830P",
      "regimen": "Liver fat in relation to clinical outcomes",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "893eP",
      "regimen": "Boarding time as a predictor of short-term mortality",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "856P",
      "regimen": "Patterns of care and treatment in Elderly patients with resected Colon Cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "876eP",
      "regimen": "Temporal and age-related patterns in mode of presentation for colorectal cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "732MO",
      "regimen": "ctDNA clearance and correlation with outcome",
      "drugs": [],
      "biomarkers": [
        "ctDNA"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "788P",
      "regimen": "Neoadjuvant Chemotherapy in Rectal Cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "867eP",
      "regimen": "Impact of Wnt/beta-catenin signalling on CAR-T cell cytotoxicity",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "CAR-T"
      ],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "747P",
      "regimen": "Regorafenib plus Irinotecan",
      "drugs": [
        "Regorafenib",
        "Irinotecan"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Phase 2",
      "trial_id": "N/A",
      "biomarkers": []
    },
    {
      "row_id": "912eTiP",
      "regimen": "SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy",
      "drugs": [
        "SCRT",
        "mFOLFOX6",
        "PD-1 Antibody"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "CRIT",
      "biomarkers": []
    },
    {
      "row_id": "819P",
      "regimen": "AI-based blood test",
      "population": "Other",
      "line": "N/A",
      "phase": "Not specified",
      "trial_id": "N/A",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "727MO",
      "regimen": "FOLFOX plus PANITUMUMAB",
      "drugs": [
        "FOLFOX",
        "PANITUMUMAB"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "N/A",
      "biomarkers": []
    },
    {
      "row_id": "872eP",
      "regimen": "Identifying fit-for-use real-world data",
      "population": "Other",
      "line": "N/A",
      "phase": "Not specified",
      "trial_id": "AZUR-1",
      "drugs": [],
      "biomarkers": [
        "MSI",
        "dMMR"
      ]
    },
    {
      "row_id": "2921eP",
      "regimen": "Medical oral nutrition supplement",
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "NUTRACT",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "854P",
      "regimen": "Immunonutrition",
      "population": "Other",
      "line": "N/A",
      "phase": "Not specified",
      "trial_id": "N/A",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "750P",
      "regimen": "Dynamic ctDNA in Predicting Response to Neoadjuvant Chemotherapy",
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "CONVERT",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "828P",
      "regimen": "Enhance immune checkpoint inhibitor efficacy",
      "population": "Other",
      "line": "N/A",
      "phase": "Not specified",
      "trial_id": "N/A",
      "drugs": [],
      "biomarkers": [
        "MSI"
      ]
    },
    {
      "row_id": "735P",
      "regimen": "Adjuvant aspirin for colorectal cancers",
      "drugs": [
        "Aspirin"
      ],
      "biomarkers": [
        "PIK3CA"
      ],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Not specified",
      "trial_id": "ASCOLT"
    },
    {
      "row_id": "771P",
      "regimen": "ctDNA-negative resection",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "NCT06562348",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "737MO",
      "regimen": "Trastuzumab deruxtecan (T-DXd)",
      "drugs": [
        "Trastuzumab deruxtecan"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Phase 2",
      "trial_id": "DESTINY-CRC02",
      "biomarkers": [
        "HER2"
      ]
    },
    {
      "row_id": "861TiP",
      "regimen": "ctDNA guided palliative systemic therapy",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "NCT06562348",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "825P",
      "regimen": "Oxaliplatin-Based Chemotherapy + Targeted Agents",
      "drugs": [
        "Oxaliplatin"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "ARCAD D",
      "biomarkers": []
    },
    {
      "row_id": "786P",
      "regimen": "Serplulimab Combined with CapeOX and Celecoxib",
      "drugs": [
        "Serplulimab",
        "CapeOX",
        "Celecoxib"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "SCAR",
      "biomarkers": []
    },
    {
      "row_id": "746P",
      "regimen": "Zanidatamab + mFOLFOX6 +/- Bevacizumab",
      "drugs": [
        "Zanidatamab",
        "mFOLFOX6",
        "Bevacizumab"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": [
        "HER2"
      ]
    },
    {
      "row_id": "817P",
      "regimen": "anti-EGFR Therapy",
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "823P",
      "regimen": "mFOLFOXIRI Following Metastasectomy",
      "drugs": [
        "mFOLFOXIRI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "FANTASTIC",
      "biomarkers": []
    },
    {
      "row_id": "866eP",
      "regimen": "toripalimab, cetuximab plus FOLFIRI",
      "drugs": [
        "toripalimab",
        "cetuximab",
        "FOLFIRI"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": "Tesla study",
      "biomarkers": []
    },
    {
      "row_id": "773P",
      "regimen": "Cadonilimab into Total Neoadjuvant Therapy",
      "drugs": [
        "Cadonilimab"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "906eTiP",
      "regimen": "neoadjuvant PD-1 vaccine PD1-Vaxx",
      "drugs": [
        "PD1-Vaxx"
      ],
      "modality": [
        "Vaccine"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "Neo-POLEM",
      "biomarkers": [
        "MSI"
      ]
    },
    {
      "row_id": "742P",
      "regimen": "real world matched study",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "Survival of patients with dMMR versus pMMR early stage colon cancer",
      "drugs": [],
      "biomarkers": [
        "dMMR"
      ]
    },
    {
      "row_id": "875eP",
      "regimen": "first line combination chemotherapy",
      "drugs": [
        "EGFR-inhibitors",
        "VEGF-inhibitors"
      ],
      "biomarkers": [
        "EGFR"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "Increased EGFR gene copy number (GCN) in prediction of outcome"
    },
    {
      "row_id": "815P",
      "regimen": "Microsatellite Instability Assessment",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "Prospective Evaluation of Deepath-MSI for Microsatellite Instability Assessment",
      "drugs": [],
      "biomarkers": [
        "MSI"
      ]
    },
    {
      "row_id": "813P",
      "regimen": "ACTION HIV",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "A LATAM Record of Patients with Anal Squamous Cell Carcinoma with and without HIV Infection",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "871eP",
      "regimen": "Molecular Profiles and Genomic Therapy",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "Molecular Profiles and Genomic Therapy in Young vs. Average-Onset Gastrointestinal (GI) Cancers",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "897eP",
      "regimen": "chemoradiation",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "Patient-reported quality of life after treatment with chemoradiation in patients with non-metastatic anal squamous cell carcinoma",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "812P",
      "regimen": "nivolumab and ipilimumab",
      "drugs": [
        "nivolumab",
        "ipilimumab"
      ],
      "biomarkers": [
        "MSI",
        "dMMR"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "The PRODIGE-74 GERCOR NIPISAFE randomized non-comparati"
    },
    {
      "row_id": "879eP",
      "regimen": "nivolumab and ipilimumab",
      "drugs": [
        "nivolumab",
        "ipilimumab"
      ],
      "biomarkers": [
        "MSI",
        "dMMR"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": "GERCOR NIPIRESCUE phase II trial"
    },
    {
      "row_id": "831P",
      "regimen": "Cadonilimab Combined with FOLFOXIRI and Bevacizumab",
      "drugs": [
        "Cadonilimab",
        "FOLFOXIRI",
        "Bevacizumab"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "Cadonilimab Combined with FOLFOXIRI and Bevacizumab as First-Line Treatment for MSS/pMMR Metastatic Colorectal Cancer",
      "biomarkers": []
    },
    {
      "row_id": "1534P",
      "regimen": "BTN1A1-Targeted Immunotherapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "855P",
      "regimen": "Larotrectinib in NTRK Fusion-Positive Colorectal Cancer",
      "drugs": [
        "Larotrectinib"
      ],
      "biomarkers": [
        "NTRK"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "888eP",
      "regimen": "Bi-specific T cell engager (BiTE) activity in Colorectal Cancer",
      "drugs": [],
      "biomarkers": [
        "EpCAM"
      ],
      "modality": [
        "Bispecific"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "768P",
      "regimen": "Adjuvant chemotherapy by ctDNA-based genomic profile",
      "drugs": [],
      "biomarkers": [
        "ctDNA"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "837P",
      "regimen": "BRAF-Targeted Therapy in Pretreated Colorectal Cancer",
      "drugs": [],
      "biomarkers": [
        "TP53"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "770P",
      "regimen": "ctDNA Testing for Adjuvant Chemotherapy Decision-Making",
      "drugs": [],
      "biomarkers": [
        "ctDNA"
      ],
      "modality": [],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "757P",
      "regimen": "Not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "757P"
    },
    {
      "row_id": "986P",
      "regimen": "NovoTTF-100L(P) in Combination with Chemotherapy",
      "drugs": [
        "NovoTTF-100L(P)",
        "Chemotherapy"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": "986P"
    },
    {
      "row_id": "847P",
      "regimen": "Not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "847P"
    },
    {
      "row_id": "ROW_2804",
      "regimen": "immunotherapy in early-stages colon cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ROW_2804"
    },
    {
      "row_id": "805P",
      "regimen": "UGT1A1 genotype-guided irinotecan dosing",
      "drugs": [
        "irinotecan"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "805P"
    },
    {
      "row_id": "772P",
      "regimen": "Perioperative atezolizumab with or without IMM-101",
      "drugs": [
        "atezolizumab",
        "IMM-101"
      ],
      "biomarkers": [
        "MSI",
        "dMMR"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Perioperative",
      "phase": "Not specified",
      "trial_id": "772P"
    },
    {
      "row_id": "794P",
      "regimen": "Fruquintinib Expanded Access Program",
      "drugs": [
        "Fruquintinib"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "mCRC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "794P"
    },
    {
      "row_id": "767P",
      "regimen": "Not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "767P"
    },
    {
      "row_id": "884eP",
      "regimen": "Not specified",
      "drugs": [],
      "biomarkers": [
        "Interleukin-1beta",
        "Interleukin-6"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "884eP"
    },
    {
      "row_id": "873eP",
      "regimen": "Not specified",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "873eP"
    },
    {
      "row_id": "ROW_3321",
      "trial_id": "ROW_3321",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_3360",
      "trial_id": "ROW_3360",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1756eP",
      "trial_id": "1756eP",
      "drugs": [],
      "biomarkers": [
        "MSI"
      ]
    },
    {
      "row_id": "ROW_4303",
      "trial_id": "ROW_4303",
      "drugs": [],
      "biomarkers": []
    }
  ],
  "head_and_neck_cancer": [
    {
      "row_id": "1",
      "regimen": "TQB2450 plus intensity-modulated radiotherapy",
      "drugs": [
        "TQB2450"
      ],
      "modality": [
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "1377P",
      "biomarkers": []
    },
    {
      "row_id": "2",
      "regimen": "neoadjuvant chemotherapy with docetaxel plus cisplatin and 5-fluorouracil",
      "drugs": [
        "docetaxel",
        "cisplatin",
        "5-fluorouracil"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "1362P",
      "biomarkers": []
    },
    {
      "row_id": "3",
      "regimen": "Paclitaxel, Cisplatin, and Capecitabine vs. Cisplatin and Fluorouracil as Induction Chemotherapy",
      "drugs": [
        "Paclitaxel",
        "Cisplatin",
        "Capecitabine",
        "Fluorouracil"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1370P",
      "biomarkers": []
    },
    {
      "row_id": "4",
      "regimen": "Anti-Angiogenic Drugs Reverse Immune Resistance",
      "drugs": [
        "Anti-Angiogenic Drugs"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1356P",
      "biomarkers": []
    },
    {
      "row_id": "5",
      "regimen": "the role of systemic therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma progressed to immunotherapy",
      "drugs": [
        "systemic therapy"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1455eP",
      "biomarkers": []
    },
    {
      "row_id": "6",
      "regimen": "PD-L1+ Tumoral Extracellular Vesicles as Biomarkers of Immune-Related Toxicities",
      "drugs": [],
      "biomarkers": [
        "PD-L1"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "318P"
    },
    {
      "row_id": "7",
      "regimen": "luvometinib (FCN-159) in recurrent or progressive pediatric low-grade glioma",
      "drugs": [
        "luvometinib (FCN-159)"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "661MO",
      "biomarkers": []
    },
    {
      "row_id": "8",
      "regimen": "Enhancing the Identification of Peri-Tumoral Regions in High-Grade Gliomas",
      "drugs": [],
      "modality": [
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "691P",
      "biomarkers": []
    },
    {
      "row_id": "9",
      "regimen": "DDX5 super-enhancer promote vasculogenic mimicry formation and metastasis",
      "drugs": [],
      "biomarkers": [
        "DDX5"
      ],
      "modality": [
        "Other"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1432P"
    },
    {
      "row_id": "10",
      "regimen": "Survival Benefit of Curative Therapy in Functionally Frail Head and Neck Cancer Patients",
      "drugs": [],
      "modality": [
        "Other"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1449eP",
      "biomarkers": []
    },
    {
      "row_id": "11",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "",
      "line": "",
      "phase": "",
      "trial_id": "ROW_4634"
    },
    {
      "row_id": "12",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "",
      "line": "",
      "phase": "",
      "trial_id": "ROW_4645"
    },
    {
      "row_id": "13",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "",
      "line": "",
      "phase": "",
      "trial_id": "ROW_4650"
    },
    {
      "row_id": "14",
      "regimen": "",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "",
      "line": "",
      "phase": "",
      "trial_id": "ROW_4665"
    },
    {
      "row_id": "15",
      "regimen": "Mechanisms and therapeutic interventions of KAT5-mediated immunotherapy resistance",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "11P"
    },
    {
      "row_id": "ROW_102",
      "regimen": "patient-derived tumour organoids for guiding treatment decisions",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1518MO",
      "regimen": "plasma exchange in melanoma",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "3071MO",
      "regimen": "Disitamab Vedotin plus Tislelizumab as Nephron-Sparing Therapy",
      "drugs": [
        "Disitamab Vedotin",
        "Tislelizumab",
        "disitamab vedotin",
        "tislelizumab"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "DISTINCT-I"
    },
    {
      "row_id": "2385MO",
      "regimen": "T-cell phenotypes and clinical efficacy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2596MO",
      "regimen": "Ipilimumab, Nivolumab, and Ciforadenant",
      "drugs": [
        "Ipilimumab",
        "Nivolumab",
        "Ciforadenant",
        "nivolumab"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1b/2",
      "trial_id": ""
    },
    {
      "row_id": "1521MO",
      "regimen": "solnerstotug combined with cemiplimab",
      "drugs": [
        "solnerstotug",
        "cemiplimab"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": ""
    },
    {
      "row_id": "LBA92",
      "regimen": "Docetaxel in Combination with Darolutamide + ADT",
      "drugs": [
        "Docetaxel",
        "Darolutamide"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 3",
      "trial_id": "ARASAFE"
    },
    {
      "row_id": "926MO",
      "regimen": "MK-1084 Monotherapy",
      "drugs": [
        "MK-1084"
      ],
      "biomarkers": [
        "KRAS"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": "KANDLELIT-001"
    },
    {
      "row_id": "927MO",
      "regimen": "Single-agent divarasib",
      "drugs": [
        "divarasib"
      ],
      "biomarkers": [
        "KRAS"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "925MO",
      "regimen": "oral Werner helicase inhibitor HRO761",
      "drugs": [
        "HRO761"
      ],
      "biomarkers": [
        "MSI",
        "dMMR"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1/Ib",
      "trial_id": ""
    },
    {
      "row_id": "1517MO",
      "regimen": "botensilimab and balstilimab",
      "drugs": [
        "botensilimab",
        "balstilimab"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1b",
      "trial_id": ""
    },
    {
      "row_id": "3069MO",
      "regimen": "durvalumab plus neoadjuvant chemotherapy",
      "drugs": [
        "durvalumab"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "MIBC",
      "line": "Perioperative",
      "phase": "Not specified",
      "trial_id": "NIAGARA"
    },
    {
      "row_id": "1516MO",
      "regimen": "personalized cancer vaccine EVX-01",
      "drugs": [
        "EVX-01"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "LBA111",
      "regimen": "upfront Magnetic Resonance Imaging Versus Transurethral Resection",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "BladderPath"
    },
    {
      "row_id": "923MO",
      "regimen": "next generation, CNS-penetrant, PARP1-selective inhibitor SNV1521",
      "drugs": [
        "SNV1521"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": ""
    },
    {
      "row_id": "16",
      "regimen": "Exploration of Post-Treatment Strategies",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1347P"
    },
    {
      "row_id": "17",
      "regimen": "Update on the phase II study",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "661MO"
    },
    {
      "row_id": "18",
      "regimen": "Development of an Interpretable Machine Learning-Based Prediction Model",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1402P"
    },
    {
      "row_id": "19",
      "regimen": "DNA methylation-based epigenetic signatures",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "665MO"
    },
    {
      "row_id": "20",
      "regimen": "Enhancing the Identification of Peri-Tumoral Regions",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "691P"
    },
    {
      "row_id": "LBA58",
      "regimen": "pembrolizumab plus lenvatinib",
      "drugs": [
        "pembrolizumab",
        "lenvatinib"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": "PLUME"
    },
    {
      "row_id": "1318O",
      "regimen": "Nimotuzumab Plus Cisplatin-Based Chemoradiotherapy",
      "drugs": [
        "Nimotuzumab",
        "Cisplatin",
        "cisplatin"
      ],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Phase 3",
      "trial_id": "1318O"
    },
    {
      "row_id": "LBA103",
      "regimen": "Oral Nutritional Supplements During Concurrent Chemoradiotherapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Chemotherapy",
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Other",
      "phase": "Not specified",
      "trial_id": "LBA103"
    },
    {
      "row_id": "2762MO",
      "regimen": "lurbinectedin + atezolizumab",
      "drugs": [
        "lurbinectedin",
        "atezolizumab"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 3",
      "trial_id": "IMforte"
    },
    {
      "row_id": "1609MO",
      "regimen": "adjuvant nivolumab vs ipilimumab",
      "drugs": [
        "nivolumab",
        "ipilimumab"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Phase 3",
      "trial_id": "CheckMate 238"
    },
    {
      "row_id": "1605MO",
      "regimen": "BNT111 in combination with cemiplimab",
      "drugs": [
        "BNT111",
        "cemiplimab"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Other",
      "phase": "Phase 2",
      "trial_id": "Not specified"
    },
    {
      "row_id": "LBA52",
      "regimen": "Nofazinlimab combined with lenvatinib",
      "drugs": [
        "Nofazinlimab",
        "lenvatinib"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 3",
      "trial_id": "LBA52"
    },
    {
      "row_id": "114MO",
      "regimen": "genomic-guided targeted therapies",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Other",
      "phase": "Not specified",
      "trial_id": "IMPRESS-Norway"
    },
    {
      "row_id": "116MO",
      "regimen": "taselisib",
      "drugs": [
        "taselisib"
      ],
      "biomarkers": [
        "PIK3CA"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Other",
      "phase": "Phase 2",
      "trial_id": "LORELEI"
    },
    {
      "row_id": "2804MO",
      "regimen": "Cancer-associated cachexia indicators",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Other"
      ],
      "population": "Other",
      "line": "Other",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "2807MO",
      "regimen": "Predicting Chemotherapy-Related severe Hematological Toxicities",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Other",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "117MO",
      "regimen": "neoadjuvant anti-PD1",
      "drugs": [],
      "biomarkers": [
        "PD1"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "1298eP",
      "regimen": "PD-1/CD20 Dual-Target Therapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Other",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "LBA60",
      "regimen": "intralesional L19IL2/L19TNF",
      "drugs": [
        "L19IL2",
        "L19TNF"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Other",
      "phase": "Not specified",
      "trial_id": "LBA60"
    },
    {
      "row_id": "ROW_994",
      "regimen": "Invited Discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Other",
      "phase": "Not specified",
      "trial_id": "ROW_994"
    },
    {
      "row_id": "ROW_790",
      "regimen": "Invited Discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Other",
      "phase": "Not specified",
      "trial_id": "ROW_790"
    },
    {
      "row_id": "ROW_774",
      "regimen": "Invited Discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Other",
      "phase": "Not specified",
      "trial_id": "ROW_774"
    },
    {
      "row_id": "ROW_796",
      "regimen": "Invited Discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Other",
      "phase": "Not specified",
      "trial_id": "ROW_796"
    },
    {
      "row_id": "ROW_1042",
      "regimen": "Invited Discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Other",
      "phase": "Not specified",
      "trial_id": "ROW_1042"
    },
    {
      "row_id": "1319O",
      "regimen": "perioperative camrelizumab plus chemotherapy",
      "drugs": [
        "camrelizumab",
        "chemotherapy"
      ],
      "biomarkers": [],
      "modality": [
        "IO",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Perioperative",
      "phase": "Phase 2",
      "trial_id": "CAMORAL"
    },
    {
      "row_id": "ROW_1286",
      "regimen": "recent data in resectable LA HNSCC",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1310",
      "regimen": "integrating novel strategies into patient care in resectable LA HNSCC",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1465",
      "regimen": "invited discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1437",
      "regimen": "invited discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1248",
      "regimen": "invited discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1293",
      "regimen": "invited discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1343",
      "regimen": "invited discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1695",
      "regimen": "invited discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1707",
      "regimen": "invited discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1057P",
      "regimen": "epidemiological pattern in testicular cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2805MO",
      "regimen": "impact of Mediterranean dietary intervention",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1471MO",
      "regimen": "adding ipilimumab to atezolizumab plus bevacizumab",
      "drugs": [
        "Ipilimumab",
        "Atezolizumab",
        "Bevacizumab",
        "atezolizumab"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "PROD"
    },
    {
      "row_id": "2806MO",
      "regimen": "effect of a multidisciplinary intervention on fatigue",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "113MO",
      "regimen": "multimodal molecular investigation of rare cancer patients",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2781P",
      "regimen": "prognostic and predictive value of CD8 intratumoral density",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2679eP",
      "regimen": "CT-based intratumoral vascular feature",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1018eTiP",
      "regimen": "Phase I trial of RGT-61159",
      "drugs": [
        "RGT-61159"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Phase 1",
      "trial_id": ""
    },
    {
      "row_id": "LBA35",
      "regimen": "EGFR×HER3 Bispecific Antibody-drug Conjugate vs Physician's Choice of Chemotherapy",
      "drugs": [
        "Iza-Bren",
        "Chemotherapy"
      ],
      "biomarkers": [],
      "modality": [
        "Bispecific",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Phase 2",
      "trial_id": "BL-B01D1"
    },
    {
      "row_id": "LBA45",
      "regimen": "Relacorilant + Nab-paclitaxel",
      "drugs": [
        "Relacorilant",
        "Nab-paclitaxel"
      ],
      "biomarkers": [],
      "modality": [
        "IO",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "GOG3073"
    },
    {
      "row_id": "1464eP",
      "regimen": "genetic heterogeneity analysis",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_3210",
      "regimen": "invited discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1450eP",
      "regimen": "locoregional recurrence analysis",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1418P",
      "regimen": "Fusobacterium nucleatum impact",
      "drugs": [],
      "biomarkers": [
        "Fusobacterium nucleatum",
        "Porphyromonas gingivalis"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "147P",
      "regimen": "gene expression panel for recurrence",
      "drugs": [],
      "biomarkers": [
        "Circulating Tumor Cells"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "LBA76",
      "regimen": "Paclitaxel-bevacizumab +/- atezolizumab",
      "drugs": [
        "Paclitaxel",
        "bevacizumab",
        "atezolizumab"
      ],
      "biomarkers": [],
      "modality": [
        "Chemotherapy",
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "IFCT-2201 ADAPTABLE"
    },
    {
      "row_id": "ROW_3256",
      "regimen": "invited discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1438P",
      "regimen": "mortality trends analysis",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1421P",
      "regimen": "cisplatin and radiotherapy",
      "drugs": [
        "cisplatin"
      ],
      "biomarkers": [],
      "modality": [
        "Chemotherapy",
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1436P",
      "regimen": "nutrition impact on kidney disease",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_3278",
      "regimen": "invited discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1446eP",
      "regimen": "multidisciplinary care survey",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1372P",
      "regimen": "Nab-Paclitaxel combined with cisplatin and PD-1 inhibitor",
      "drugs": [
        "Nab-Paclitaxel",
        "cisplatin"
      ],
      "biomarkers": [
        "PD-1"
      ],
      "modality": [
        "Chemotherapy",
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": ""
    },
    {
      "row_id": "1426P",
      "regimen": "real-world use of pembrolizumab",
      "drugs": [
        "pembrolizumab"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "HNSCC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1463eP",
      "regimen": "gas metabolite patterns analysis",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1373P",
      "regimen": "Tislelizumab combined with TP Regimen",
      "drugs": [
        "Tislelizumab",
        "tislelizumab"
      ],
      "biomarkers": [],
      "modality": [
        "IO",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": ""
    },
    {
      "row_id": "1387P",
      "regimen": "tumor heterogeneity analysis",
      "drugs": [],
      "biomarkers": [
        "EBV-DNA"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1371P",
      "regimen": "Nivolumab plus chemoradiotherapy",
      "drugs": [
        "Nivolumab",
        "nivolumab",
        "cisplatin"
      ],
      "biomarkers": [],
      "modality": [
        "IO",
        "Chemotherapy",
        "Radiotherapy"
      ],
      "population": "NPC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1444eP",
      "regimen": "lymph nodes and extranodal extension impact",
      "drugs": [],
      "biomarkers": [
        "HPV-positive"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1403P",
      "regimen": "transcriptomic signatures validation",
      "drugs": [
        "nivolumab"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "HNSCC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1338P",
      "regimen": "neoadjuvant PARP inhibitor and immunotherapy",
      "drugs": [
        "PARP inhibitor",
        "immunotherapy"
      ],
      "biomarkers": [
        "HPV-negative"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "PRIME H&N Study"
    },
    {
      "row_id": "1346P",
      "regimen": "sequential immune checkpoint inhibitor and cetuximab-based chemotherapy",
      "drugs": [
        "immune checkpoint inhibitor",
        "cetuximab",
        "chemotherapy"
      ],
      "biomarkers": [],
      "modality": [
        "IO",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Pooled Analysis"
    },
    {
      "row_id": "1351P",
      "regimen": "low-dose weekly carboplatin and paclitaxel metronomic chemotherapy",
      "drugs": [
        "carboplatin",
        "paclitaxel"
      ],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Phase 2",
      "trial_id": "Not specified"
    },
    {
      "row_id": "1345P",
      "regimen": "omission of elective neck irradiation",
      "drugs": [],
      "biomarkers": [
        "pT3-T4 Oral Squamous Cell Carcinoma",
        "pN0 Neck"
      ],
      "modality": [
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "1359P",
      "regimen": "1st line treatment in recurrent/metastatic head and neck squamous cell carcinoma",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "REALKEY"
    },
    {
      "row_id": "1374P",
      "regimen": "exploratory analysis of microenvironment-informed delta radiomics",
      "drugs": [
        "pembrolizumab",
        "gemcitabine",
        "cisplatin"
      ],
      "biomarkers": [],
      "modality": [
        "Not specified"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "NEOSPACE"
    },
    {
      "row_id": "1428P",
      "regimen": "anti-PD-1 immune checkpoint inhibitors combined with cetuximab",
      "drugs": [
        "anti-PD-1",
        "cetuximab"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "1353P",
      "regimen": "discontinuing immune checkpoint inhibitors",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "1405P",
      "regimen": "AI informed virtual immunocyte profiling",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Not specified"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "VIPER"
    },
    {
      "row_id": "80MO",
      "regimen": "durvalumab plus tremelimumab",
      "drugs": [
        "durvalumab",
        "tremelimumab"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "IMMUNOBIL GER"
    },
    {
      "row_id": "1659P",
      "regimen": "neoadjuvant immunotherapy",
      "drugs": [
        "cetuximab"
      ],
      "biomarkers": [
        "PD-L1"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "NRG-HN014"
    },
    {
      "row_id": "1415P",
      "regimen": "PD-L1 expression analysis",
      "drugs": [],
      "biomarkers": [
        "PD-L1",
        "TIGIT",
        "CD155"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1352P",
      "regimen": "Amivantamab plus paclitaxel",
      "drugs": [
        "Amivantamab",
        "paclitaxel"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1341P",
      "regimen": "follow-up strategy assessment",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": "HETECO"
    },
    {
      "row_id": "128P",
      "regimen": "anti-PD(L)1 immunotherapy",
      "drugs": [],
      "biomarkers": [
        "PTI Score"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1701eTiP",
      "regimen": "neoadjuvant immunotherapy with response-adapted treatment",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Phase 3",
      "trial_id": "NRG-HN014"
    },
    {
      "row_id": "LBA27",
      "regimen": "SM-1 combined with temozolomide",
      "drugs": [
        "SM-1",
        "temozolomide"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "LBA51",
      "regimen": "Atezolizumab plus Bevacizumab",
      "drugs": [
        "Atezolizumab",
        "Bevacizumab",
        "atezolizumab"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "",
      "phase": "Phase IIIb",
      "trial_id": "IKF-035/ABC-HCC"
    },
    {
      "row_id": "555MO",
      "regimen": "Datopotamab deruxtecan plus durvalumab",
      "drugs": [
        "Datopotamab deruxtecan",
        "durvalumab"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "487MO",
      "regimen": "CDK4/6 inhibitors",
      "drugs": [],
      "biomarkers": [
        "HER2"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "720eP",
      "regimen": "Therapeutic Drug Monitoring",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "81MO",
      "regimen": "Tinengotinib in advanced CCA",
      "drugs": [
        "Tinengotinib"
      ],
      "biomarkers": [
        "FGFR"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "LBA85",
      "regimen": "short-course versus long-course chemotherapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "",
      "phase": "Phase 3",
      "trial_id": ""
    },
    {
      "row_id": "ROW_4035",
      "regimen": "consolidation and ablative therapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_4053",
      "regimen": "Invited Discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_4120",
      "regimen": "Circulating EBV DNA for treatment selection",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1408P",
      "regimen": "C-FAST assessment",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2280MO",
      "regimen": "Control Groups in Cancer Trials",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "213eP",
      "regimen": "Therapeutic Drug Monitoring",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "FORAGER-1",
      "regimen": "LY3866288 in FGFR3-altered advanced solid tumors",
      "drugs": [
        "LY3866288"
      ],
      "biomarkers": [
        "FGFR3"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 1",
      "trial_id": "FORAGER-1"
    },
    {
      "row_id": "SAKK 01/10",
      "regimen": "Single-dose carboplatin and involved-node radiotherapy",
      "drugs": [
        "carboplatin"
      ],
      "modality": [
        "Chemotherapy",
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": "SAKK 01/10",
      "biomarkers": []
    },
    {
      "row_id": "SunRISe-4",
      "regimen": "Neoadjuvant gemcitabine intravesical system (TAR-200) + cetrelimab",
      "drugs": [
        "gemcitabine",
        "cetrelimab"
      ],
      "modality": [
        "Intravesical"
      ],
      "population": "MIBC",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "SunRISe-4",
      "biomarkers": []
    },
    {
      "row_id": "START-001",
      "regimen": "invikafusp alfa as monotherapy",
      "drugs": [
        "invikafusp alfa"
      ],
      "modality": [
        "Bispecific"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": "START-001",
      "biomarkers": []
    },
    {
      "row_id": "METROPH",
      "regimen": "Metronomic Cyclophosphamide VS Doxorubicin",
      "drugs": [
        "Cyclophosphamide",
        "Doxorubicin"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "METROPH",
      "biomarkers": []
    },
    {
      "row_id": "COTESARC",
      "regimen": "Combination of MEK and PDL-1 inhibitors",
      "drugs": [
        "MEK",
        "PDL-1 inhibitors"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase I-II",
      "trial_id": "COTESARC",
      "biomarkers": []
    },
    {
      "row_id": "PETRANHA",
      "regimen": "saruparib + androgen receptor pathway inhibitors",
      "drugs": [
        "saruparib",
        "androgen receptor pathway inhibitors"
      ],
      "modality": [
        "TKI"
      ],
      "population": "mPC",
      "line": "1L",
      "phase": "Phase 1/2",
      "trial_id": "PETRANHA",
      "biomarkers": []
    },
    {
      "row_id": "AMPLITUDE",
      "regimen": "niraparib and abiraterone acetate plus prednisone",
      "drugs": [
        "niraparib",
        "abiraterone acetate",
        "prednisone"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 3",
      "trial_id": "AMPLITUDE",
      "biomarkers": []
    },
    {
      "row_id": "1515MO",
      "regimen": "mRNA-4359 Plus Pembrolizumab",
      "drugs": [
        "mRNA-4359",
        "Pembrolizumab",
        "pembrolizumab"
      ],
      "biomarkers": [
        "PD-L1"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1515MO"
    },
    {
      "row_id": "1520MO",
      "regimen": "anti-CD137 switch antibody agonist STA551 as monotherapy and in combination with atezolizumab",
      "drugs": [
        "STA551",
        "atezolizumab"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": "1520MO",
      "biomarkers": []
    },
    {
      "row_id": "1519MO",
      "regimen": "systemic STING agonist BI 1703880 plus ezabenlimab",
      "drugs": [
        "BI 1703880",
        "ezabenlimab"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase Ia",
      "trial_id": "1519MO",
      "biomarkers": []
    },
    {
      "row_id": "1522MO",
      "regimen": "INCA33890, A PD-1/TGFbetaR2 Bispecific Antibody",
      "drugs": [
        "INCA33890"
      ],
      "modality": [
        "Bispecific"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": "1522MO",
      "biomarkers": []
    },
    {
      "row_id": "2802O",
      "regimen": "Home-based supervised physical activity for metastatic cancer patients receiving oral targeted therapy",
      "drugs": [
        "oral targeted therapy"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 3",
      "trial_id": "2802O",
      "biomarkers": []
    },
    {
      "row_id": "2687MO",
      "regimen": "nivolumab+/-relatlimab",
      "drugs": [
        "nivolumab",
        "relatlimab"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase II",
      "trial_id": "2687MO",
      "biomarkers": []
    },
    {
      "row_id": "2688MO",
      "regimen": "FOG-001, a first-in-class direct beta-catenin:TCF4 inhibitor",
      "drugs": [
        "FOG-001"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1/2",
      "trial_id": "2688MO",
      "biomarkers": []
    },
    {
      "row_id": "ROW_97",
      "regimen": "Invited Discussant",
      "trial_id": "ROW_97",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_126",
      "regimen": "Combinations of cell death modulators and other therapies",
      "trial_id": "ROW_126",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_128",
      "regimen": "Invited Discussant",
      "trial_id": "ROW_128",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_132",
      "regimen": "Invited Discussant",
      "trial_id": "ROW_132",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_137",
      "regimen": "The rationale behind drug combinations",
      "trial_id": "ROW_137",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_181",
      "regimen": "Invited Discussant",
      "trial_id": "ROW_181",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2420MO",
      "regimen": "Effects of prostate radiotherapy (RT) on synchronous, metastatic, hormone-sensitive prostate cancer (mHSPC)",
      "trial_id": "2420MO",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "LBA99",
      "regimen": "BIOmarker driven trial of Vegf2 inhibitor in Advanced or metastatic Sarcoma",
      "trial_id": "LBA99",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2691MO",
      "regimen": "Twenty year survival of advanced gastrointestinal stromal tumours treated with imatinib",
      "trial_id": "2691MO",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2605MO",
      "regimen": "Final efficacy data and biomarker analysis from the clear cell cohort of CALYPSO",
      "trial_id": "2605MO",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "3072MO",
      "regimen": "Datopotamab deruxtecan + rilvegostomig",
      "drugs": [
        "Datopotamab deruxtecan",
        "rilvegostomig"
      ],
      "population": "mUC",
      "line": "2L",
      "phase": "Phase 2",
      "trial_id": "TROPION-PanTumor",
      "biomarkers": []
    },
    {
      "row_id": "924MO",
      "regimen": "ART6043 as monotherapy and in combination with olaparib",
      "drugs": [
        "ART6043",
        "olaparib"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "2690MO",
      "regimen": "pimicotinib",
      "drugs": [
        "pimicotinib"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 3",
      "trial_id": "MANEUVER",
      "biomarkers": []
    },
    {
      "row_id": "922MO",
      "regimen": "AMT-116",
      "drugs": [
        "AMT-116"
      ],
      "population": "Other",
      "phase": "Phase I/II",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "2689MO",
      "regimen": "Chidamide and Toripalimab",
      "drugs": [
        "Chidamide",
        "Toripalimab",
        "toripalimab"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase II",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "2592MO",
      "regimen": "Fruquintinib plus sintilimab versus axitinib or everolimus",
      "drugs": [
        "Fruquintinib",
        "sintilimab",
        "axitinib",
        "everolimus"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "3012MO",
      "regimen": "Metastasis dissemination and divergence timing",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": "TRACERx"
    },
    {
      "row_id": "1320O",
      "regimen": "Postoperative adjuvant radiochemotherapy with cisplatin vs. aRCH plus pembrolizumab",
      "drugs": [
        "cisplatin",
        "pembrolizumab"
      ],
      "biomarkers": [],
      "modality": [
        "Chemotherapy",
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Not specified",
      "trial_id": "ADRI"
    },
    {
      "row_id": "1229eP",
      "regimen": "Biparatopic FRalpha-Targeting ADC",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "ADC"
      ],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": "GenSci140"
    },
    {
      "row_id": "3196eP",
      "regimen": "Determining Line of Therapy with LLMs",
      "modality": [
        "IO"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "3196eP",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2808MO",
      "regimen": "Impact of Proton Pump Inhibitors on Immunotherapy Outcomes",
      "modality": [
        "IO"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "2808MO",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1603MO",
      "regimen": "Adjuvant cemiplimab vs placebo",
      "drugs": [
        "cemiplimab"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Phase 3",
      "trial_id": "C-POST",
      "biomarkers": []
    },
    {
      "row_id": "LBA59",
      "regimen": "Combined Percutaneous Hepatic Perfusion with Ipilimumab plus Nivolumab",
      "drugs": [
        "Ipilimumab",
        "Nivolumab",
        "nivolumab"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Phase 2",
      "trial_id": "CHOPIN",
      "biomarkers": []
    },
    {
      "row_id": "2543MO",
      "regimen": "Multimodal Digital Therapeutic for Cancer-Related Fatigue",
      "modality": [
        "IO"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "2543MO",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1MO",
      "regimen": "Placental features overexpression",
      "modality": [
        "IO"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1MO",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "CN157",
      "regimen": "Enhancing Adherence to Oral Hormone Therapy",
      "modality": [
        "IO"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "CN157",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1317O",
      "regimen": "neoadjuvant durvalumab plus chemoradiotherapy (CRT) followed by adjuvant durvalumab immunotherapy (IO)",
      "drugs": [
        "durvalumab"
      ],
      "modality": [
        "IO",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Phase 3",
      "trial_id": "CompARE",
      "biomarkers": []
    },
    {
      "row_id": "1348MO",
      "regimen": "tiragolumab (tira) + atezolizumab (atezo) and atezo + placebo (pbo) as first-line (1L) treatment",
      "drugs": [
        "tiragolumab",
        "atezolizumab"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": "SKYSCRAPER-09",
      "biomarkers": [
        "PD-L1"
      ]
    },
    {
      "row_id": "CN90",
      "regimen": "chemoradiation",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "CN90"
    },
    {
      "row_id": "2209eP",
      "regimen": "intravenous (ivST) versus oral systemic treatment (oST)",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2209eP"
    },
    {
      "row_id": "2949eP",
      "regimen": "oral treatments",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2949eP"
    },
    {
      "row_id": "1065MO",
      "regimen": "AZD5335, a folate receptor alpha (FRalpha)-targeted antibody-drug conjugate",
      "drugs": [
        "AZD5335"
      ],
      "biomarkers": [
        "FRalpha"
      ],
      "modality": [
        "ADC"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": "1065MO"
    },
    {
      "row_id": "LBA41",
      "regimen": "baseline multiplex cytokine profiling",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 3",
      "trial_id": "LBA41"
    },
    {
      "row_id": "LBA43",
      "regimen": "TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate",
      "drugs": [
        "TUB-040"
      ],
      "biomarkers": [],
      "modality": [
        "ADC"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": "LBA43"
    },
    {
      "row_id": "294MO",
      "regimen": "giredestrant or tamoxifen (tam)",
      "drugs": [
        "giredestrant",
        "tamoxifen"
      ],
      "biomarkers": [
        "HER2"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "294MO"
    },
    {
      "row_id": "2613MO",
      "regimen": "Nivolumab plus Ipilimumab Therapy",
      "drugs": [
        "Nivolumab",
        "Ipilimumab",
        "nivolumab"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "mUC",
      "line": "1L",
      "phase": "Phase 1",
      "trial_id": "COSMIC 313"
    },
    {
      "row_id": "1323MO",
      "regimen": "Evorpacept in combination with Pembrolizumab",
      "drugs": [
        "Evorpacept",
        "Pembrolizumab",
        "pembrolizumab"
      ],
      "biomarkers": [
        "PD-L1"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": "ASPEN-03"
    },
    {
      "row_id": "LBA44",
      "regimen": "Durvalumab + Paclitaxel/Carboplatin + Bevacizumab followed by Durvalumab, Bevacizumab + Olaparib maintenance",
      "drugs": [
        "Durvalumab",
        "Paclitaxel",
        "Carboplatin",
        "Bevacizumab",
        "Olaparib",
        "durvalumab",
        "carboplatin"
      ],
      "biomarkers": [],
      "modality": [
        "ADC",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Maintenance",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1510TiP",
      "regimen": "Oral Fecal Microbiota Capsule for Reprogramming Immunity",
      "drugs": [
        "Oral Fecal Microbiota Capsule"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": ""
    },
    {
      "row_id": "1247MO",
      "regimen": "Molecular Landscape of Distinct Follicular Lymphoma Histologic Grades",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "889eP",
      "regimen": "adjuvant treatment in localized colorectal cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2189P",
      "regimen": "Active oncologic treatment in the last month of life",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1970",
      "regimen": "oral SERD in HR+, HER2- MBC",
      "drugs": [
        "oral SERD"
      ],
      "biomarkers": [
        "HR+",
        "HER2-",
        "HER2"
      ],
      "modality": [],
      "population": "MIBC",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2559P",
      "regimen": "cognitive behavioral therapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1994",
      "regimen": "Invited Discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_2031",
      "regimen": "Invited Discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "919O",
      "regimen": "oral IAG933 in advanced mesothelioma",
      "drugs": [
        "oral IAG933"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Phase 1",
      "trial_id": ""
    },
    {
      "row_id": "876eP",
      "regimen": "patterns in mode of presentation for colorectal cancer",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "732MO",
      "regimen": "ctDNA clearance in INTERCEPT colorectal cancer study",
      "drugs": [],
      "biomarkers": [
        "ctDNA"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1250MO",
      "regimen": "Second-Line Therapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "2L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2890P",
      "regimen": "Remote Monitoring of Patients Receiving Oral or Intravenous Anticancer Treatments",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1244MO",
      "regimen": "Response Assessment with Sequential Whole Body Magnetic Resonance Imaging",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2849P",
      "regimen": "low-molecular-weight heparins vs direct oral anticoagulants",
      "drugs": [
        "low-molecular-weight heparins",
        "direct oral anticoagulants"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "2849P",
      "biomarkers": []
    },
    {
      "row_id": "916O",
      "regimen": "INCB161734, A Novel Oral KRAS G12D Inhibitor",
      "drugs": [
        "INCB161734"
      ],
      "population": "Other",
      "phase": "Phase 1",
      "trial_id": "916O",
      "biomarkers": [
        "KRAS"
      ]
    },
    {
      "row_id": "727MO",
      "regimen": "FOLFOX plus PANITUMUMAB",
      "drugs": [
        "FOLFOX",
        "PANITUMUMAB"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "727MO",
      "biomarkers": []
    },
    {
      "row_id": "2921eP",
      "regimen": "medical oral nutrition supplement",
      "drugs": [
        "medical oral nutrition supplement"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "2921eP",
      "biomarkers": []
    },
    {
      "row_id": "LBA46",
      "regimen": "TAK228 in Combination With Intravenous Weekly Paclitaxel",
      "drugs": [
        "TAK228",
        "Intravenous Weekly Paclitaxel"
      ],
      "population": "Other",
      "phase": "Phase 2",
      "trial_id": "LBA46",
      "biomarkers": []
    },
    {
      "row_id": "737MO",
      "regimen": "Trastuzumab deruxtecan (T-DXd)",
      "drugs": [
        "Trastuzumab deruxtecan"
      ],
      "biomarkers": [
        "HER2"
      ],
      "population": "mCRC",
      "phase": "Phase 2",
      "trial_id": "737MO"
    },
    {
      "row_id": "1324MO",
      "regimen": "evorpacept in combination with pembrolizumab and chemotherapy",
      "drugs": [
        "evorpacept",
        "pembrolizumab",
        "chemotherapy"
      ],
      "population": "Other",
      "phase": "Phase 2",
      "trial_id": "1324MO",
      "biomarkers": []
    },
    {
      "row_id": "1327MO",
      "regimen": "Amivantamab in recurrent/metastatic head & neck squamous cell cancer after disease progression on checkpoint inhibition and chemotherapy",
      "drugs": [
        "Amivantamab"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Phase 1",
      "trial_id": "OrigAM",
      "biomarkers": []
    },
    {
      "row_id": "2951eP",
      "regimen": "Efficacy of Ketamine for Oral And Pharyngeal Mucositis Pain",
      "drugs": [
        "Ketamine"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 3",
      "trial_id": "KARM",
      "biomarkers": []
    },
    {
      "row_id": "297MO",
      "regimen": "Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain",
      "drugs": [
        "Pegfilgrastim"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 3",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "979P",
      "regimen": "Phase 1 dose escalation study of T-1101 (Tosylate) Capsule",
      "drugs": [
        "T-1101 (Tosylate)"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "2600MO",
      "regimen": "Comparing ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer",
      "drugs": [
        "ipilimumab",
        "nivolumab"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "SUNNIFORECAST",
      "biomarkers": [
        "PD-L1"
      ]
    },
    {
      "row_id": "LBA40",
      "regimen": "WES-derived Aneuploidy score identifies MMRd patients with reduced benefit from immunotherapy",
      "drugs": [],
      "biomarkers": [
        "MMRd"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 3",
      "trial_id": "AtTEnd/ENGOT-EN7"
    },
    {
      "row_id": "2599MO",
      "regimen": "Soluble MAdCAM-1 predicts outcomes in patients with metastatic renal cell carcinoma",
      "drugs": [],
      "biomarkers": [
        "MAdCAM-1"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "323MO",
      "regimen": "Efficacy of adjuvant anti-PD-L1 avelumab by tumor infiltrating lymphocytes for high-risk triple negative breast cancer",
      "drugs": [
        "avelumab"
      ],
      "biomarkers": [
        "PD-L1"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Phase 3",
      "trial_id": "A-BRAVE"
    },
    {
      "row_id": "2595MO",
      "regimen": "Comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment",
      "drugs": [
        "Ipilimumab",
        "Nivolumab",
        "nivolumab"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "SUNNIFORECAST",
      "biomarkers": []
    },
    {
      "row_id": "1328MO",
      "regimen": "hypofractionated radiotherapy + pembrolizumab",
      "drugs": [
        "pembrolizumab"
      ],
      "modality": [
        "Radiotherapy",
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1328MO",
      "biomarkers": []
    },
    {
      "row_id": "1849MO",
      "regimen": "encorafenib + binimetinib",
      "drugs": [
        "encorafenib",
        "binimetinib"
      ],
      "population": "mUC",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "1849MO",
      "biomarkers": []
    },
    {
      "row_id": "731MO",
      "regimen": "telisotuzumab adizutecan + bevacizumab",
      "drugs": [
        "telisotuzumab adizutecan",
        "bevacizumab"
      ],
      "population": "Other",
      "line": "3L",
      "phase": "Not specified",
      "trial_id": "731MO",
      "biomarkers": []
    },
    {
      "row_id": "295MO",
      "regimen": "neoadjuvant chemotherapy",
      "drugs": [],
      "biomarkers": [
        "Ki-67"
      ],
      "modality": [
        "Chemotherapy",
        "Neoadjuvant"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "295MO"
    },
    {
      "row_id": "1249MO",
      "regimen": "Bexmarilimab + Azacitidine",
      "drugs": [
        "Bexmarilimab",
        "Azacitidine"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1/2",
      "trial_id": "1249MO",
      "biomarkers": []
    },
    {
      "row_id": "1329MO",
      "regimen": "enfortumab vedotin + pembrolizumab",
      "drugs": [
        "enfortumab vedotin",
        "pembrolizumab"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "1329MO",
      "biomarkers": []
    },
    {
      "row_id": "293MO",
      "regimen": "neoadjuvant vepdegestrant or anastrozole",
      "drugs": [
        "vepdegestrant",
        "anastrozole"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "293MO",
      "biomarkers": [
        "HER2"
      ]
    },
    {
      "row_id": "1846MO",
      "regimen": "olomorasib in patients with KRAS G12C-mutant NSCLC",
      "drugs": [
        "olomorasib"
      ],
      "biomarkers": [
        "KRAS G12C",
        "KRAS"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1846MO"
    },
    {
      "row_id": "2593MO",
      "regimen": "LAG3 expression patterns and immunotherapy response",
      "drugs": [],
      "biomarkers": [
        "LAG3"
      ],
      "modality": [
        "IO"
      ],
      "population": "mUC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2593MO"
    },
    {
      "row_id": "1325MO",
      "regimen": "Retifanlimab Alone Or In Combination With Anti-LAG3 +/- Anti-TIM3 mAbs",
      "drugs": [
        "Retifanlimab"
      ],
      "biomarkers": [
        "PD-L1",
        "LAG3",
        "TIM3"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1325MO"
    },
    {
      "row_id": "1016eTiP",
      "regimen": "LY4066434 in KRAS-mutant solid tumors",
      "drugs": [
        "LY4066434"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 1",
      "trial_id": "1016eTiP",
      "biomarkers": [
        "KRAS"
      ]
    },
    {
      "row_id": "292MO",
      "regimen": "Durvalumab in Combination with Neoadjuvant Chemotherapy",
      "drugs": [
        "Durvalumab",
        "durvalumab"
      ],
      "modality": [
        "IO",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "292MO",
      "biomarkers": []
    },
    {
      "row_id": "1246MO",
      "regimen": "R-CHOP and Anti-CD19 CAR T Therapies",
      "drugs": [
        "R-CHOP",
        "Anti-CD19 CAR T"
      ],
      "modality": [
        "Chemotherapy",
        "CAR-T"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1246MO",
      "biomarkers": []
    },
    {
      "row_id": "2828P",
      "regimen": "Pirfenidone in the Treatment of Radiation-Induced Oral Mucositis",
      "drugs": [
        "Pirfenidone"
      ],
      "modality": [
        "Other"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "2828P",
      "biomarkers": []
    },
    {
      "row_id": "730MO",
      "regimen": "Trifluridine/Tipiracil + Capecitabine + Bevacizumab",
      "drugs": [
        "Trifluridine",
        "Tipiracil",
        "Capecitabine",
        "Bevacizumab"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": "TriComB",
      "biomarkers": []
    },
    {
      "row_id": "1566P",
      "regimen": "Intratumoral JNJ-87704916 + Cetrelimab",
      "drugs": [
        "JNJ-87704916",
        "Cetrelimab"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "2594MO",
      "regimen": "KIM-1 levels association",
      "biomarkers": [
        "KIM-1"
      ],
      "modality": [
        "Not specified"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "COSMIC-313",
      "drugs": []
    },
    {
      "row_id": "2229P",
      "regimen": "Oxaliplatin + Irinotecan Liposome + 5-FU/LV",
      "drugs": [
        "Oxaliplatin",
        "Irinotecan Liposome",
        "5-FU",
        "LV"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "1248MO",
      "regimen": "Venetoclax-containing regimen",
      "drugs": [
        "Venetoclax"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "CN126",
      "regimen": "ondansetron oral soluble film-based regimens",
      "drugs": [
        "ondansetron"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "734MO",
      "regimen": "blood-based early cancer detection test",
      "modality": [
        "Not specified"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1330MO",
      "regimen": "neoadjuvant-adjuvant pembrolizumab + SOC",
      "drugs": [
        "pembrolizumab"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "LBA34",
      "regimen": "sirexatamab + bevacizumab + chemotherapy",
      "drugs": [
        "sirexatamab",
        "bevacizumab"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Phase 2",
      "trial_id": "DeFianCe Trial",
      "biomarkers": []
    },
    {
      "row_id": "1245MO",
      "regimen": "Mitoxantrone Hydrochloride Liposome + Chidamide",
      "drugs": [
        "Mitoxantrone Hydrochloride Liposome",
        "Chidamide"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "1388P",
      "regimen": "Incidence Patterns and Survival Trajectories",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": "1388P"
    },
    {
      "row_id": "1458eP",
      "regimen": "Biomarker and Genomic Landscape Study",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": "1458eP"
    },
    {
      "row_id": "1437P",
      "regimen": "Prediction of 1-Year Recurrence-Free Survival",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": "1437P"
    },
    {
      "row_id": "1337P",
      "regimen": "superselective intra-arterial cisplatin and concomitant radiotherapy",
      "drugs": [
        "cisplatin"
      ],
      "biomarkers": [],
      "modality": [
        "Chemotherapy",
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": "1337P"
    },
    {
      "row_id": "1419P",
      "regimen": "radiation therapy",
      "modality": [
        "Radiotherapy"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1419P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1401P",
      "regimen": "APG-157-Induced Anti-Tumor Immune Remodeling",
      "modality": [
        "IO"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1401P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1390P",
      "regimen": "Becotatug Vedotin combined with Pucotenlimab",
      "drugs": [
        "Becotatug Vedotin",
        "Pucotenlimab"
      ],
      "population": "Other",
      "phase": "Phase 2",
      "trial_id": "1390P",
      "biomarkers": []
    },
    {
      "row_id": "1461eP",
      "regimen": "miRNA Signatures as Diagnostic Biomarker",
      "biomarkers": [
        "miRNA"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1461eP",
      "drugs": []
    },
    {
      "row_id": "ROW_3399",
      "regimen": "Maintenance therapy after chemo-immunotherapy",
      "modality": [
        "Maintenance"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "ROW_3399",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "235eP",
      "regimen": "Chemotherapy Survival Status",
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "235eP",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "LBA106",
      "regimen": "Niraparib in relapsed mesothelioma",
      "drugs": [
        "Niraparib"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "phase": "Phase 2",
      "trial_id": "LBA106",
      "biomarkers": []
    },
    {
      "row_id": "1424P",
      "regimen": "Comparative Diagnostic Performance of CBCT and CT",
      "modality": [
        "Other"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1424P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1465eTiP",
      "regimen": "Tislelizumab Combined with Chemotherapy Followed by Radiotherapy/Adaptive Surgery",
      "drugs": [
        "Tislelizumab",
        "tislelizumab"
      ],
      "modality": [
        "IO",
        "Chemotherapy",
        "Radiotherapy"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1465eTiP",
      "biomarkers": []
    },
    {
      "row_id": "LBA26",
      "regimen": "LY4064809 (STX-478), a pan-mutant-selective PI3Kalpha inhibitor",
      "drugs": [
        "LY4064809",
        "STX-478"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "phase": "Phase 1",
      "trial_id": "LBA26",
      "biomarkers": []
    },
    {
      "row_id": "LBA48",
      "regimen": "buparlisib plus paclitaxel",
      "drugs": [
        "buparlisib",
        "paclitaxel"
      ],
      "biomarkers": [
        "PD-1",
        "PD-L1"
      ],
      "modality": [
        "Chemotherapy",
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 3",
      "trial_id": "BURAN"
    },
    {
      "row_id": "662MO",
      "regimen": "concomitant radiotherapy with olaparib and temozolomide",
      "drugs": [
        "olaparib",
        "temozolomide"
      ],
      "modality": [
        "Radiotherapy",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": "OLA-TMZ-RTE-01",
      "biomarkers": []
    },
    {
      "row_id": "200eP",
      "regimen": "dual PD-L1 and TGFbeta inhibition",
      "drugs": [],
      "biomarkers": [
        "PD-L1",
        "TGFbeta"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1817MO",
      "regimen": "osimertinib",
      "drugs": [
        "osimertinib"
      ],
      "biomarkers": [
        "EGFR",
        "EGFRm"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "LAURA"
    },
    {
      "row_id": "1671P",
      "regimen": "cutaneous angiosarcoma treatment",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1425P",
      "regimen": "locally advanced head and neck cancer treatment",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "486MO",
      "regimen": "camizestrant plus CDK4/6 inhibitor",
      "drugs": [
        "camizestrant",
        "CDK4/6 inhibitor"
      ],
      "biomarkers": [
        "ESR1m",
        "HER2"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "SERENA-6"
    },
    {
      "row_id": "1462eP",
      "regimen": "risk prediction involving KIF13B variant",
      "drugs": [],
      "biomarkers": [
        "KIF13B c.*3163G>A"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1392P",
      "regimen": "avelumab in high-risk oral potentially malignant disorders",
      "drugs": [
        "avelumab"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "Impede"
    },
    {
      "row_id": "LBA25",
      "regimen": "Culmerciclib Plus Fulvestrant",
      "drugs": [
        "Culmerciclib",
        "Fulvestrant"
      ],
      "modality": [
        "TKI",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 3",
      "trial_id": "CULMINATE-2",
      "biomarkers": [
        "HER2"
      ]
    },
    {
      "row_id": "LBA22",
      "regimen": "sacituzumab govitecan + pembrolizumab vs chemotherapy + pembrolizumab",
      "drugs": [
        "sacituzumab govitecan",
        "pembrolizumab",
        "chemotherapy"
      ],
      "biomarkers": [
        "PD-L1"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "660MO",
      "regimen": "regorafenib plus temozolomide with or without radiotherapy",
      "drugs": [
        "regorafenib",
        "temozolomide"
      ],
      "modality": [
        "TKI",
        "Chemotherapy",
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 1",
      "trial_id": "REGOM",
      "biomarkers": []
    },
    {
      "row_id": "1349P",
      "regimen": "Tipifarnib and alpelisib",
      "drugs": [
        "Tipifarnib",
        "alpelisib"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 1",
      "trial_id": "KURRENT-HN",
      "biomarkers": []
    },
    {
      "row_id": "LBA11",
      "regimen": "Neoadjuvant Toripalimab Plus Lenvatinib and GEMOX",
      "drugs": [
        "Toripalimab",
        "Lenvatinib",
        "GEMOX",
        "toripalimab"
      ],
      "modality": [
        "IO",
        "Chemotherapy",
        "Neoadjuvant"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Phase II-III",
      "trial_id": "",
      "biomarkers": []
    },
    {
      "row_id": "1399P",
      "regimen": "Prognostic model driven by explainable AI",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1399P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "663MO",
      "regimen": "IL13Ralpha2-targeted CAR-T cell therapy",
      "modality": [
        "CAR-T"
      ],
      "population": "Other",
      "phase": "Phase 1",
      "trial_id": "663MO",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1469MO",
      "regimen": "Liver resection versus continued atezolizumab plus bevacizumab",
      "drugs": [
        "atezolizumab",
        "bevacizumab"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1469MO",
      "biomarkers": []
    },
    {
      "row_id": "1851MO",
      "regimen": "Pembrolizumab plus chemotherapy",
      "drugs": [
        "pembrolizumab",
        "chemotherapy"
      ],
      "biomarkers": [
        "PD-L1"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 3",
      "trial_id": "1851MO"
    },
    {
      "row_id": "485MO",
      "regimen": "Adding Palbociclib to HER2 and Endocrine Therapy",
      "drugs": [
        "Palbociclib",
        "HER2",
        "Endocrine Therapy"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "485MO",
      "biomarkers": [
        "HER2"
      ]
    },
    {
      "row_id": "1336P",
      "regimen": "Definitive Radiotherapy Regimens",
      "modality": [
        "Radiotherapy"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1336P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1459eP",
      "regimen": "Adjuvant Fluoropyrimidines Following Definitive Chemoradiotherapy",
      "drugs": [
        "Fluoropyrimidines"
      ],
      "modality": [
        "Chemotherapy",
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Not specified",
      "trial_id": "1459eP",
      "biomarkers": []
    },
    {
      "row_id": "1404P",
      "regimen": "Analysis Of Comorbidities And Demographic Factors",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1404P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1409P",
      "regimen": "NOTCH pathway in head and neck squamous cell carcinoma",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1409P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1443TiP",
      "regimen": "Pembrolizumab and Radiotherapy",
      "drugs": [
        "Pembrolizumab",
        "pembrolizumab"
      ],
      "modality": [
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 3",
      "trial_id": "EORTC 2014-HNCG PROLoNg",
      "biomarkers": []
    },
    {
      "row_id": "1395P",
      "regimen": "FID-007 Plus Cetuximab",
      "drugs": [
        "FID-007",
        "Cetuximab"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "R/M HNSCC",
      "biomarkers": []
    },
    {
      "row_id": "2214MO",
      "regimen": "telisotuzumab adizutecan",
      "drugs": [
        "telisotuzumab adizutecan"
      ],
      "modality": [
        "ADC"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": "ABBV-400; Temab-A",
      "biomarkers": []
    },
    {
      "row_id": "1710MO",
      "regimen": "Belzutifan for Advanced Pancreatic Neuroendocrine Tumors",
      "drugs": [
        "Belzutifan"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "LITESPARK-015",
      "biomarkers": []
    },
    {
      "row_id": "1360P",
      "regimen": "Concurrent Weekly Carboplatin, Paclitaxel, and Cetuximab",
      "drugs": [
        "Carboplatin",
        "Paclitaxel",
        "Cetuximab",
        "carboplatin"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Not specified",
      "trial_id": "Recurrent or Metastatic Head and Neck Squamous Cell",
      "biomarkers": []
    },
    {
      "row_id": "1331P",
      "regimen": "induction chemotherapy with cisplatin, 5-fluorouracil and docetaxel",
      "drugs": [
        "cisplatin",
        "5-fluorouracil",
        "docetaxel"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "GORTEC 2019-01",
      "biomarkers": []
    },
    {
      "row_id": "1440TiP",
      "regimen": "Tislelizumab Plus Gemcitabine/Capecitabine versus Tislelizumab Plus Gemcitabine/Cisplatin",
      "drugs": [
        "Tislelizumab",
        "Gemcitabine",
        "Capecitabine",
        "Cisplatin",
        "tislelizumab",
        "gemcitabine",
        "cisplatin"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 3",
      "trial_id": "Recurrent/Metastatic Nasopharyngeal",
      "biomarkers": []
    },
    {
      "row_id": "1375P",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1375P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1334P",
      "regimen": "neoadjuvant pembrolizumab combined with low-dose cisplatin and 5-fluorouracil",
      "drugs": [
        "pembrolizumab",
        "cisplatin",
        "5-fluorouracil"
      ],
      "modality": [
        "IO",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "1334P",
      "biomarkers": []
    },
    {
      "row_id": "1342P",
      "regimen": "neoadjuvant anti-PD1 with low-dose cisplatin/5-fluorouracil",
      "drugs": [
        "anti-PD1",
        "cisplatin",
        "5-fluorouracil"
      ],
      "modality": [
        "IO",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "1342P",
      "biomarkers": []
    },
    {
      "row_id": "1451eP",
      "regimen": "neoadjuvant chemoimmunotherapy",
      "modality": [
        "Chemotherapy",
        "IO"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "1451eP",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1321O",
      "regimen": "Concurrent Chemoradiotherapy with/without Adjuvant Capecitabine",
      "drugs": [
        "Capecitabine"
      ],
      "modality": [
        "Chemotherapy",
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Phase 3",
      "trial_id": "1321O",
      "biomarkers": []
    },
    {
      "row_id": "1413P",
      "regimen": "Cisplatin Chemoresistance via the EGFR-JAK2-STAT3 Pathway",
      "drugs": [
        "Cisplatin",
        "cisplatin"
      ],
      "biomarkers": [
        "DDAH1",
        "EGFR",
        "JAK2",
        "STAT3"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1413P"
    },
    {
      "row_id": "1453eP",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1453eP",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1434P",
      "regimen": "High-Dose Cisplatin Chemoradiotherapy",
      "drugs": [
        "Cisplatin",
        "cisplatin"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1434P",
      "biomarkers": []
    },
    {
      "row_id": "LBA70",
      "regimen": "association of radiomic features +/- on-treatment ctDNA detection",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "LBA70",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1034MO",
      "regimen": "Targeted Alpha Therapy",
      "drugs": [
        "Targeted Alpha Therapy"
      ],
      "modality": [
        "Radiotherapy"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1034MO",
      "biomarkers": []
    },
    {
      "row_id": "1365P",
      "regimen": "risk-adapted phase 2 study",
      "drugs": [
        "HPV circulating tumor DNA"
      ],
      "population": "Other",
      "phase": "Phase 2",
      "trial_id": "1365P",
      "biomarkers": []
    },
    {
      "row_id": "1414P",
      "regimen": "Next Generation Sequencing (NGS) Analysis",
      "drugs": [
        "Next Generation Sequencing"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1414P",
      "biomarkers": []
    },
    {
      "row_id": "1384P",
      "regimen": "Photoimmunotherapy",
      "drugs": [
        "Photoimmunotherapy"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1384P",
      "biomarkers": []
    },
    {
      "row_id": "1397P",
      "regimen": "personalized drug therapy selection",
      "drugs": [
        "patient-derived organoids"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1397P",
      "biomarkers": []
    },
    {
      "row_id": "457eP",
      "regimen": "neoadjuvant chemotherapy",
      "drugs": [
        "chemotherapy"
      ],
      "modality": [
        "Neoadjuvant"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "457eP",
      "biomarkers": []
    },
    {
      "row_id": "1442TiP",
      "regimen": "Peri-radiotherapy immunotherapy",
      "drugs": [
        "immunotherapy"
      ],
      "modality": [
        "IO",
        "Radiotherapy"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1442TiP",
      "biomarkers": []
    },
    {
      "row_id": "270eP",
      "regimen": "Peritumoral desmoplasia",
      "drugs": [],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "270eP",
      "biomarkers": []
    },
    {
      "row_id": "1422P",
      "regimen": "PD-1 inhibitor or cetuximab combined with chemotherapy",
      "drugs": [
        "PD-1 inhibitor",
        "cetuximab",
        "chemotherapy"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "1422P",
      "biomarkers": []
    },
    {
      "row_id": "1457eP",
      "regimen": "TPF regimen chrono-chemotherapy combined with cisplatin concurrent chemoradiotherapy",
      "drugs": [
        "TPF regimen",
        "cisplatin",
        "chemoradiotherapy"
      ],
      "modality": [
        "Chemotherapy",
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "1457eP",
      "biomarkers": []
    },
    {
      "row_id": "664MO",
      "regimen": "larotrectinib",
      "drugs": [
        "larotrectinib"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "664MO",
      "biomarkers": []
    },
    {
      "row_id": "504P",
      "regimen": "First-Line (1L) treatment in HR+ HER2- Metastatic Breast Cancer",
      "drugs": [
        "ESR1 mutations",
        "AKT Pathway"
      ],
      "biomarkers": [
        "ESR1m",
        "AKTp",
        "HER2"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "504P"
    },
    {
      "row_id": "1035MO",
      "regimen": "Prediction Tool for Malnutrition and Sarcopenia",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": "GETNE-S2109"
    },
    {
      "row_id": "489MO",
      "regimen": "vepdegestrant vs fulvestrant",
      "drugs": [
        "vepdegestrant",
        "fulvestrant"
      ],
      "biomarkers": [
        "ESR1m",
        "HER2"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1460eP",
      "regimen": "Personalized Targeted Therapies",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1340P",
      "regimen": "GM-CSF on prevention and treatment of oral mucositis",
      "drugs": [
        "GM-CSF"
      ],
      "biomarkers": [],
      "modality": [
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": "ChiCTR2300068457"
    },
    {
      "row_id": "1417P",
      "regimen": "immunonutrition on oral mucositis",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "479P",
      "regimen": "H4K8la/CXCL10-driven M2 polarization",
      "drugs": [
        "doxorubicin"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1354P",
      "regimen": "discontinuation of immune checkpoint inhibitors",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Other",
      "phase": "Not specified",
      "trial_id": "1354P"
    },
    {
      "row_id": "1350P",
      "regimen": "Immuno-Chemotherapy Alone",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Phase 2",
      "trial_id": "1350P"
    },
    {
      "row_id": "2216MO",
      "regimen": "Nab-Paclitaxel and Gemcitabine with/without intravenous VCN-01",
      "drugs": [
        "Nab-Paclitaxel",
        "Gemcitabine",
        "VCN-01",
        "gemcitabine"
      ],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Other",
      "phase": "Phase 2b",
      "trial_id": "2216MO"
    },
    {
      "row_id": "1429P",
      "regimen": "cytotoxic chemotherapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Other",
      "phase": "Not specified",
      "trial_id": "1429P"
    },
    {
      "row_id": "1427P",
      "regimen": "photoimmunotherapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Other",
      "phase": "Not specified",
      "trial_id": "1427P"
    },
    {
      "row_id": "1411P",
      "regimen": "PD-1 inhibitors",
      "drugs": [],
      "biomarkers": [
        "PD-1"
      ],
      "modality": [],
      "population": "Other",
      "line": "Other",
      "phase": "Not specified",
      "trial_id": "1411P"
    },
    {
      "row_id": "1344P",
      "regimen": "neoadjuvant immunochemotherapy and radical surgery",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "1344P"
    },
    {
      "row_id": "ROW_4310",
      "trial_id": "ROW_4310",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1380P",
      "regimen": "metronomic capecitabine adjuvant chemotherapy",
      "drugs": [
        "capecitabine"
      ],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Not specified",
      "trial_id": "1380P",
      "biomarkers": []
    },
    {
      "row_id": "1333P",
      "regimen": "adjuvant radiotherapy",
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Not specified",
      "trial_id": "1333P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1433P",
      "trial_id": "1433P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1364P",
      "trial_id": "1364P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_4330",
      "trial_id": "ROW_4330",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2281MO",
      "trial_id": "2281MO",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1407P",
      "trial_id": "1407P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1441TiP",
      "regimen": "SIRPalpha monoclonal antibody BI 770371 in combination with pembrolizumab",
      "drugs": [
        "BI 770371",
        "pembrolizumab",
        "cetuximab"
      ],
      "phase": "Phase Ib",
      "trial_id": "1441TiP",
      "biomarkers": []
    },
    {
      "row_id": "1708MO",
      "regimen": "ZG005 in combination with etoposide and cisplatin",
      "drugs": [
        "ZG005",
        "etoposide",
        "cisplatin"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "1708MO",
      "biomarkers": []
    },
    {
      "row_id": "1343P",
      "regimen": "Neoadjuvant Tislelizumab Plus Chemotherapy",
      "drugs": [
        "Tislelizumab",
        "tislelizumab"
      ],
      "modality": [
        "Chemotherapy",
        "Neoadjuvant"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "NeoSPOT",
      "biomarkers": []
    },
    {
      "row_id": "536MO",
      "regimen": "SHR-A1811 plus pertuzumab",
      "drugs": [
        "SHR-A1811",
        "pertuzumab"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": "Not specified",
      "biomarkers": [
        "HER2"
      ]
    },
    {
      "row_id": "1347P",
      "regimen": "Neoadjuvant PD-1 Inhibitor Combined with Chemotherapy",
      "drugs": [
        "PD-1 Inhibitor"
      ],
      "modality": [
        "Chemotherapy",
        "Neoadjuvant"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "1378P",
      "regimen": "Envafolimab plus chemoradiotherapy",
      "drugs": [
        "Envafolimab"
      ],
      "modality": [
        "Chemotherapy",
        "Radiotherapy",
        "Neoadjuvant"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "1358P",
      "regimen": "Combination of Cadonilimab and Low-Dose Radiotherapy",
      "drugs": [
        "Cadonilimab"
      ],
      "modality": [
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "1335P",
      "regimen": "Neoadjuvant Tislelizumab Plus Platinum-Based Doublet Chemotherapy",
      "drugs": [
        "Tislelizumab",
        "tislelizumab"
      ],
      "modality": [
        "Chemotherapy",
        "Neoadjuvant"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "1376P",
      "regimen": "Immune Checkpoint Inhibitors",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": "1376P"
    },
    {
      "row_id": "665MO",
      "regimen": "DNA methylation-based epigenetic signatures",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": "665MO"
    },
    {
      "row_id": "652eTiP",
      "regimen": "FWD1802 with CDK4/6 inhibitors and mTOR inhibitor",
      "drugs": [
        "FWD1802",
        "CDK4/6 inhibitors",
        "mTOR inhibitor"
      ],
      "biomarkers": [
        "ER",
        "HER2"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Phase 1",
      "trial_id": "652eTiP"
    },
    {
      "row_id": "1339P",
      "regimen": "Neoadjuvant Chemotherapy Plus Toripalimab",
      "drugs": [
        "Toripalimab",
        "toripalimab"
      ],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "1339P"
    },
    {
      "row_id": "11P",
      "regimen": "KAT5-mediated immunotherapy resistance interventions",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": "11P"
    },
    {
      "row_id": "1332P",
      "regimen": "SBRT followed by neoadjuvant chemo-immunotherapy of Sintilimab plus docetaxel and cisplatin",
      "drugs": [
        "Sintilimab",
        "docetaxel",
        "cisplatin"
      ],
      "biomarkers": [],
      "modality": [
        "Radiotherapy",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "1332P"
    },
    {
      "row_id": "1383P",
      "regimen": "Cetuximab-Enhanced Induction Chemotherapy",
      "drugs": [
        "Cetuximab"
      ],
      "biomarkers": [],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": "1383P"
    },
    {
      "row_id": "1355P",
      "regimen": "docetaxel plus pembrolizumab combination treatment",
      "drugs": [
        "docetaxel",
        "pembrolizumab"
      ],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Phase 2",
      "trial_id": "1355P"
    },
    {
      "row_id": "1456eP",
      "regimen": "Gunagratinib in patients with head and neck cancer",
      "drugs": [
        "Gunagratinib"
      ],
      "biomarkers": [
        "FGFR"
      ],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": "1456eP"
    },
    {
      "row_id": "1386P",
      "regimen": "Deep Learning-Based Time-Habitat Longitudinal MRI Radiomics Model",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "",
      "phase": "Not specified",
      "trial_id": "1386P"
    },
    {
      "row_id": "1454eP",
      "regimen": "Benmelstobart Combined with Anlotinib and Chemotherapy",
      "drugs": [
        "Benmelstobart",
        "Anlotinib"
      ],
      "modality": [
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "1454eP",
      "biomarkers": []
    },
    {
      "row_id": "1382P",
      "regimen": "Next-generation sequencing detection of Epstein-Barr virus and microbiome signatures",
      "drugs": [],
      "biomarkers": [
        "Epstein-Barr virus"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1382P"
    },
    {
      "row_id": "1396P",
      "regimen": "Circulating tumor DNA for Minimal Disease Detection",
      "drugs": [],
      "biomarkers": [
        "ctDNA"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "1396P"
    },
    {
      "row_id": "1423P",
      "regimen": "Neoadjuvant Immunotherapy",
      "drugs": [],
      "population": "Other",
      "line": "Neoadjuvant",
      "phase": "Not specified",
      "trial_id": "1423P",
      "biomarkers": []
    },
    {
      "row_id": "1389P",
      "regimen": "Becotatug Vedotin in combination with Pucotenlimab",
      "drugs": [
        "Becotatug Vedotin",
        "Pucotenlimab"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": "1389P",
      "biomarkers": []
    },
    {
      "row_id": "1381P",
      "regimen": "Adjuvant treatment for metastatic nasopharyngeal carcinoma",
      "drugs": [],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Not specified",
      "trial_id": "1381P",
      "biomarkers": []
    },
    {
      "row_id": "ROW_4665",
      "population": "Other",
      "trial_id": "ROW_4665",
      "drugs": [],
      "biomarkers": []
    }
  ],
  "renal_cancer": [
    {
      "row_id": "3070MO",
      "regimen": "LY3866288",
      "drugs": [
        "LY3866288"
      ],
      "biomarkers": [
        "FGFR3"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": "FORAGER-1"
    },
    {
      "row_id": "2596MO",
      "regimen": "Ipilimumab + Nivolumab + Ciforadenant",
      "drugs": [
        "Ipilimumab",
        "Nivolumab",
        "Ciforadenant",
        "nivolumab"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 1b/2",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "2592MO",
      "regimen": "Fruquintinib + Sintilimab vs Axitinib or Everolimus",
      "drugs": [
        "Fruquintinib",
        "Sintilimab",
        "Axitinib",
        "Everolimus"
      ],
      "modality": [
        "IO",
        "TKI"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "2604P",
      "regimen": "Cabozantinib + KO-2806",
      "drugs": [
        "Cabozantinib",
        "KO-2806"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 1",
      "trial_id": "FIT-001",
      "biomarkers": []
    },
    {
      "row_id": "2650P",
      "regimen": "Metastasis-directed therapies",
      "drugs": [],
      "modality": [
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "KAIROS",
      "biomarkers": []
    },
    {
      "row_id": "2635P",
      "regimen": "Immune checkpoint inhibitors",
      "drugs": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "LBA94",
      "regimen": "Lenvatinib + Everolimus vs Cabozantinib",
      "drugs": [
        "Lenvatinib",
        "Everolimus",
        "Cabozantinib"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "2680eP",
      "regimen": "Immune checkpoint inhibitor combination",
      "drugs": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "FUMAHR",
      "biomarkers": []
    },
    {
      "row_id": "2639P",
      "regimen": "Immune-checkpoint inhibitors rechallenge",
      "drugs": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "2638P",
      "regimen": "Anlotinib + Everolimus",
      "drugs": [
        "Anlotinib",
        "Everolimus"
      ],
      "modality": [
        "IO",
        "TKI"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": "UC-001",
      "biomarkers": []
    },
    {
      "row_id": "2665eP",
      "regimen": "Combined immune checkpoint and TKI therapy",
      "drugs": [],
      "modality": [
        "IO",
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "2609P",
      "regimen": "Tumor-Informed Whole Genome-Based (WGS) ctDNA Assay",
      "modality": [
        "IO"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "2609P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2603P",
      "regimen": "lenvatinib + pembrolizumab",
      "drugs": [
        "lenvatinib",
        "pembrolizumab",
        "sunitinib"
      ],
      "population": "MIBC",
      "line": "1L",
      "phase": "Phase 3",
      "trial_id": "CLEAR",
      "biomarkers": []
    },
    {
      "row_id": "2624P",
      "regimen": "nivolumab + ipilimumab",
      "drugs": [
        "nivolumab",
        "ipilimumab",
        "sunitinib"
      ],
      "population": "MIBC",
      "phase": "Not specified",
      "trial_id": "2624P",
      "biomarkers": []
    },
    {
      "row_id": "2669eP",
      "regimen": "Spatial Transcriptomics",
      "modality": [
        "IO"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "2669eP",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2675eP",
      "regimen": "Shared Genetic and Proteomic Architecture",
      "modality": [
        "IO"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "2675eP",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2683eTiP",
      "regimen": "genetically-modified Tie-2 expressing monocytes",
      "population": "MIBC",
      "phase": "Phase 1",
      "trial_id": "2683eTiP",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2808MO",
      "regimen": "Proton Pump Inhibitors",
      "modality": [
        "IO"
      ],
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "2808MO",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2606P",
      "regimen": "Transcriptomic predictors",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "2606P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "LBA96",
      "regimen": "Pembrolizumab-based Regimens",
      "drugs": [
        "pembrolizumab"
      ],
      "population": "MIBC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "KEYMAKER-U03",
      "biomarkers": []
    },
    {
      "row_id": "2619P",
      "regimen": "Real-World Practice Patterns",
      "population": "MIBC",
      "phase": "Not specified",
      "trial_id": "2619P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2636P",
      "regimen": "Patient Perceptions of Cure",
      "population": "MIBC",
      "phase": "Not specified",
      "trial_id": "2636P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2643P",
      "regimen": "Urinary microbiome diversity",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "2643P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2641P",
      "regimen": "Systemic immunosuppressive and pro-inflammatory milieu",
      "population": "MIBC",
      "phase": "Not specified",
      "trial_id": "2641P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2625P",
      "regimen": "[177Lu]Lu-PSMA-617",
      "population": "MIBC",
      "line": "1L",
      "phase": "Phase 2",
      "trial_id": "RENALUT",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2631P",
      "regimen": "Unmet Needs & Disparities in Kidney Cancer",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "2631P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2614P",
      "regimen": "Recurrence After Local Treatment",
      "population": "MIBC",
      "phase": "Not specified",
      "trial_id": "UroCCR Ndeg213",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2622P",
      "regimen": "systemic immunotherapy +/- resection",
      "modality": [
        "IO"
      ],
      "population": "MIBC",
      "phase": "Not specified",
      "trial_id": "UroCCR Ndeg193",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "LBA95",
      "regimen": "Neoadjuvant immunotherapy",
      "modality": [
        "IO"
      ],
      "population": "MIBC",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "NESCIO",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2671eP",
      "regimen": "Sarcomatoid Dedifferentiation",
      "population": "MIBC",
      "phase": "Not specified",
      "trial_id": "ARON-1",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2651P",
      "regimen": "Cabozantinib and Sunitinib",
      "drugs": [
        "cabozantinib",
        "sunitinib"
      ],
      "population": "MIBC",
      "phase": "Not specified",
      "trial_id": "TOG",
      "biomarkers": []
    },
    {
      "row_id": "2607P",
      "regimen": "Belzutifan after PD-(L)1 inhibitor and >=2 VEGFR-TKIs",
      "drugs": [
        "Belzutifan"
      ],
      "population": "Other",
      "line": "2L",
      "phase": "Not specified",
      "trial_id": "LITESPARK-005",
      "biomarkers": []
    },
    {
      "row_id": "2629P",
      "regimen": "First Line treatment in metastatic renal cell carcinoma",
      "population": "mRCC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "Real World",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "LBA93",
      "regimen": "Adjuvant durvalumab monotherapy or combined with tremelimumab",
      "drugs": [
        "durvalumab",
        "tremelimumab"
      ],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Phase 3",
      "trial_id": "RAMPART",
      "biomarkers": []
    },
    {
      "row_id": "2642P",
      "regimen": "Immunotherapy responsiveness in clear cell renal cell carcinoma",
      "population": "ccRCC",
      "phase": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2657eP",
      "regimen": "Single cell RNA sequencing study in renal cell carcinoma",
      "population": "Other",
      "phase": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2661eP",
      "regimen": "Autophagic regulation leading to metastasis in chromophobe renal cell carcinoma",
      "population": "Other",
      "phase": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2623P",
      "regimen": "Cadonilimab Plus Lenvatinib in previously immunotherapy-treated advanced clear cell renal cell carcinoma",
      "drugs": [
        "Cadonilimab",
        "Lenvatinib"
      ],
      "population": "ccRCC",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "CLEAR-IT",
      "biomarkers": []
    },
    {
      "row_id": "2660eP",
      "regimen": "TKIs Plus PD-1 Inhibitor Therapy",
      "population": "mRCC",
      "phase": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2616P",
      "regimen": "Belzutifan versus everolimus in previously treated advanced renal cell carcinoma",
      "drugs": [
        "Belzutifan",
        "everolimus"
      ],
      "population": "RCC",
      "line": "2L",
      "phase": "Not specified",
      "trial_id": "LITESPARK-005",
      "biomarkers": []
    },
    {
      "row_id": "2618P",
      "regimen": "Immuno-oncology-based combinations in advanced renal cell carcinoma",
      "population": "aRCC",
      "phase": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2621P",
      "regimen": "Adjuvant penpulimab in very high-risk clear cell renal cell carcinoma",
      "drugs": [
        "penpulimab"
      ],
      "population": "ccRCC",
      "line": "Adjuvant",
      "phase": "Phase 2",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "2634P",
      "regimen": "PD-1 blockade plus tyrosine kinase inhibitor in advanced renal cell carcinoma",
      "drugs": [
        "PD-1 blockade",
        "tyrosine kinase inhibitor"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "2630P",
      "regimen": "Single-Nucleus Atlas of Collecting Duct Carcinoma",
      "population": "Other",
      "phase": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2654eP",
      "regimen": "Multi-Omic Analysis of Collecting Duct Carcinoma",
      "population": "Other",
      "phase": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2649P",
      "regimen": "Patient experience of services in kidney cancer",
      "population": "Other",
      "phase": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2666eP",
      "regimen": "immune checkpoint inhibition",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1038",
      "regimen": "real-world data",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1053",
      "regimen": "TKIs",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2663eP",
      "regimen": "different treatment options",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "MIBC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2681eP",
      "regimen": "immunotherapy-based combinations",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "ARON-1 mu"
    },
    {
      "row_id": "2662eP",
      "regimen": "combination immunotherapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2673eP",
      "regimen": "genomic profiling",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "MIBC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2664eP",
      "regimen": "Metastatectomy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "MIBC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2678eP",
      "regimen": "Cytoreductive Nephrectomy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "MIBC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2667eP",
      "regimen": "Dialysis Status",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2620P",
      "regimen": "Systemic Therapies",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "MIBC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2647P",
      "regimen": "Immune Checkpoint Inhibitor-based Therapies",
      "drugs": [],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "MIBC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2602P",
      "regimen": "iparomlimab and tuvonralimab plus lenvatinib",
      "drugs": [
        "iparomlimab",
        "tuvonralimab",
        "lenvatinib"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "MIBC",
      "line": "Not specified",
      "phase": "Phase 1b",
      "trial_id": ""
    },
    {
      "row_id": "2648P",
      "regimen": "Sintilimab in Combination with Axitinib and Stereotactic Radiotherapy",
      "drugs": [
        "Sintilimab",
        "Axitinib"
      ],
      "biomarkers": [],
      "modality": [
        "IO",
        "Radiotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": ""
    },
    {
      "row_id": "2626P",
      "regimen": "cabozantinib plus nivolumab",
      "drugs": [
        "cabozantinib",
        "nivolumab"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "MIBC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "CaboCombo"
    },
    {
      "row_id": "2628P",
      "regimen": "registry study",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2627P",
      "regimen": "HIF2-dependent Regulation",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2682eTiP",
      "regimen": "neoadjuvant zanzalintinib plus nivolumab",
      "drugs": [
        "zanzalintinib",
        "nivolumab"
      ],
      "biomarkers": [],
      "modality": [
        "IO"
      ],
      "population": "MIBC",
      "line": "Neoadjuvant",
      "phase": "Phase 2",
      "trial_id": "EXPLORE-RCC"
    },
    {
      "row_id": "2676eP",
      "regimen": "Schwann Cell-Mediated Mechanisms",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "ROW_1284",
      "regimen": "Invited Discussant",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "1",
      "regimen": "immunotherapy",
      "phase": "Phase 3",
      "trial_id": "2601P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2",
      "regimen": "Immune-Combinations",
      "drugs": [
        "pembrolizumab"
      ],
      "population": "mRCC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "2645P",
      "biomarkers": []
    },
    {
      "row_id": "3",
      "regimen": "systemic treatment",
      "population": "mRCC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "2658eP",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "4",
      "regimen": "Cabozantinib and Nivolumab",
      "drugs": [
        "Cabozantinib",
        "Nivolumab"
      ],
      "population": "mccRCC",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "2591O",
      "biomarkers": []
    },
    {
      "row_id": "5",
      "regimen": "adjuvant pembrolizumab",
      "drugs": [
        "pembrolizumab"
      ],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Not specified",
      "trial_id": "2659eP",
      "biomarkers": []
    },
    {
      "row_id": "6",
      "regimen": "Adjuvant Immune Checkpoint Inhibition",
      "phase": "Not specified",
      "trial_id": "2612P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "7",
      "regimen": "Ipilimumab",
      "drugs": [
        "Ipilimumab"
      ],
      "population": "mccRCC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "2637P",
      "biomarkers": []
    },
    {
      "row_id": "8",
      "regimen": "adjuvant Pembrolizumab",
      "drugs": [
        "pembrolizumab"
      ],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Not specified",
      "trial_id": "2672eP",
      "biomarkers": []
    },
    {
      "row_id": "9",
      "regimen": "nivolumab-based immunotherapy",
      "drugs": [
        "nivolumab"
      ],
      "population": "mccRCC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2674eP",
      "biomarkers": []
    },
    {
      "row_id": "10",
      "regimen": "systemic cancer treatment",
      "phase": "Phase 3",
      "trial_id": "2617P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "11",
      "regimen": "Immunotherapy",
      "phase": "Not specified",
      "trial_id": "2670eP",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "12",
      "regimen": "Belzutifan Plus Lenvatinib",
      "drugs": [
        "Belzutifan",
        "Lenvatinib"
      ],
      "population": "ccRCC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "2615P",
      "biomarkers": []
    },
    {
      "row_id": "13",
      "regimen": "first-line treatment decisions",
      "phase": "Not specified",
      "trial_id": "2655eP",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "14",
      "regimen": "liquid biopsy assay",
      "phase": "Not specified",
      "trial_id": "2608P",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "15",
      "regimen": "intratumoral vascular feature",
      "phase": "Not specified",
      "trial_id": "2679eP",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "16",
      "regimen": "[68Ga]Ga-DPI-4452 PET/CT",
      "population": "Other",
      "phase": "Not specified",
      "trial_id": "2597MO",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "17",
      "regimen": "Nivolumab plus Ipilimumab Therapy",
      "drugs": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "population": "mccRCC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "2613MO",
      "biomarkers": []
    },
    {
      "row_id": "18",
      "regimen": "Novel Therapies",
      "phase": "Not specified",
      "trial_id": "ROW_1882",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "19",
      "regimen": "carboplatin dosing optimization",
      "phase": "Not specified",
      "trial_id": "2940eP",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2961eP",
      "regimen": "Carboplatin dose calculation based on renal function assessment",
      "drugs": [
        "carboplatin"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "",
      "biomarkers": []
    },
    {
      "row_id": "1530P",
      "regimen": "NUC-7738 and PD-1 Inhibition",
      "drugs": [
        "NUC-7738"
      ],
      "biomarkers": [
        "PD-1"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2861P",
      "regimen": "Meldonium in metastatic renal cell carcinoma",
      "drugs": [
        "Meldonium"
      ],
      "modality": [],
      "population": "mRCC",
      "line": "Not specified",
      "phase": "Phase 1/2",
      "trial_id": "",
      "biomarkers": []
    },
    {
      "row_id": "2598MO",
      "regimen": "Intratumor Mycobiome Promotes Clear Cell Renal Cell Carcinoma Progression",
      "drugs": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "",
      "biomarkers": []
    },
    {
      "row_id": "2600MO",
      "regimen": "Ipilimumab/Nivolumab versus standard of care",
      "drugs": [
        "Ipilimumab",
        "Nivolumab",
        "nivolumab"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "SUNNIFORECAST",
      "biomarkers": [
        "PD-L1"
      ]
    },
    {
      "row_id": "2599MO",
      "regimen": "Soluble MAdCAM-1 predicts outcomes in metastatic renal cell carcinoma",
      "drugs": [],
      "modality": [],
      "population": "mRCC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "",
      "biomarkers": []
    },
    {
      "row_id": "2595MO",
      "regimen": "Ipilimumab plus Nivolumab vs standard of care",
      "drugs": [
        "Ipilimumab",
        "Nivolumab",
        "nivolumab"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "SUNNIFORECAST",
      "biomarkers": []
    },
    {
      "row_id": "1547P",
      "regimen": "Acquired Resistance to Checkpoint Inhibitors",
      "drugs": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "",
      "biomarkers": []
    },
    {
      "row_id": "2610MO",
      "regimen": "Genomic Analysis of Papillary Renal Cell Carcinoma",
      "drugs": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "",
      "biomarkers": []
    },
    {
      "row_id": "2963eP",
      "regimen": "Nivolumab",
      "drugs": [
        "Nivolumab",
        "nivolumab"
      ],
      "biomarkers": [
        "GDF-15"
      ],
      "modality": [
        "IO"
      ],
      "population": "mRCC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2593MO",
      "regimen": "Immunotherapy response in metastatic renal cell carcinoma",
      "drugs": [],
      "biomarkers": [
        "LAG3"
      ],
      "modality": [
        "IO"
      ],
      "population": "mRCC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2594MO",
      "regimen": "Circulating kidney injury molecule-1 levels with clinical outcomes",
      "drugs": [],
      "biomarkers": [
        "KIM-1"
      ],
      "modality": [],
      "population": "aRCC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "COSMIC-313"
    },
    {
      "row_id": "64eP",
      "regimen": "Patient-Derived Organoids in Renal Cell Carcinoma",
      "drugs": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "",
      "biomarkers": []
    },
    {
      "row_id": "277eP",
      "regimen": "First-Line Immune Checkpoint Blockade",
      "drugs": [],
      "modality": [
        "IO"
      ],
      "population": "mRCC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "",
      "biomarkers": []
    },
    {
      "row_id": "44eP",
      "regimen": "Biologically Targeted Dual Adaptive and Innate Nano-Immunotherapy",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "254eP",
      "regimen": "Urinary Sediment SNORD4A as a Novel Diagnostic Biomarker",
      "drugs": [],
      "biomarkers": [
        "SNORD4A"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "68eP",
      "regimen": "Secretory GPX3 promotes lung metastasis",
      "drugs": [],
      "biomarkers": [
        "GPX3"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified"
    },
    {
      "row_id": "228eP",
      "regimen": "Impact on immunotherapy outcomes",
      "drugs": [],
      "biomarkers": [
        "ABCA1",
        "ABCG1"
      ],
      "modality": [
        "IO"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "CHOMET"
    },
    {
      "row_id": "2605MO",
      "regimen": "Final efficacy data and biomarker analysis",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2632P",
      "regimen": "Second-line patterns and outcomes",
      "drugs": [],
      "biomarkers": [],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2652eP",
      "regimen": "Succinate-dehydrogenase B protein expression and prognosis",
      "drugs": [],
      "biomarkers": [
        "succinate-dehydrogenase B"
      ],
      "modality": [],
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": ""
    },
    {
      "row_id": "2601P",
      "regimen": "immunotherapy",
      "drugs": [
        "immunotherapy"
      ],
      "modality": [
        "IO"
      ],
      "population": "mUC",
      "line": "1L",
      "phase": "Phase 3",
      "trial_id": "2601P",
      "biomarkers": []
    },
    {
      "row_id": "2645P",
      "regimen": "Immune-Combinations",
      "drugs": [
        "Immune-Combinations"
      ],
      "modality": [
        "IO"
      ],
      "population": "mUC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "2645P",
      "biomarkers": []
    },
    {
      "row_id": "2658eP",
      "regimen": "systemic treatment",
      "drugs": [
        "systemic treatment"
      ],
      "modality": [
        "IO"
      ],
      "population": "mUC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "2658eP",
      "biomarkers": []
    },
    {
      "row_id": "2591O",
      "regimen": "Cabozantinib and Nivolumab",
      "drugs": [
        "Cabozantinib",
        "Nivolumab",
        "nivolumab"
      ],
      "modality": [
        "IO"
      ],
      "population": "mUC",
      "line": "2L",
      "phase": "Phase 2",
      "trial_id": "2591O",
      "biomarkers": []
    },
    {
      "row_id": "2659eP",
      "regimen": "adjuvant pembrolizumab",
      "drugs": [
        "pembrolizumab"
      ],
      "modality": [
        "IO"
      ],
      "population": "mUC",
      "line": "Adjuvant",
      "phase": "Not specified",
      "trial_id": "2659eP",
      "biomarkers": []
    },
    {
      "row_id": "2612P",
      "regimen": "Adjuvant Immune Checkpoint Inhibition",
      "drugs": [
        "Immune Checkpoint Inhibition"
      ],
      "modality": [
        "IO"
      ],
      "population": "mUC",
      "line": "Adjuvant",
      "phase": "Not specified",
      "trial_id": "2612P",
      "biomarkers": []
    },
    {
      "row_id": "ROW_1431",
      "population": "Other",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2637P",
      "regimen": "First Line Ipilimumab",
      "drugs": [
        "Ipilimumab",
        "nivolumab"
      ],
      "population": "mUC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "2672eP",
      "regimen": "Adjuvant Pembrolizumab",
      "drugs": [
        "Pembrolizumab",
        "pembrolizumab"
      ],
      "population": "MIBC",
      "line": "Adjuvant",
      "phase": "Not specified",
      "trial_id": "ARON-1",
      "biomarkers": []
    },
    {
      "row_id": "2674eP",
      "regimen": "Nivolumab-based immunotherapy",
      "drugs": [
        "Nivolumab",
        "nivolumab"
      ],
      "population": "MIBC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "biomarkers": []
    },
    {
      "row_id": "2617P",
      "regimen": "Coaching on side effects of systemic cancer treatment",
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 3",
      "trial_id": "PREPARE",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2670eP",
      "biomarkers": [
        "SPP1"
      ],
      "population": "MIBC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": []
    },
    {
      "row_id": "2615P",
      "regimen": "Belzutifan Plus Lenvatinib",
      "drugs": [
        "Belzutifan",
        "Lenvatinib"
      ],
      "population": "mUC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "LITESPARK-010",
      "biomarkers": []
    },
    {
      "row_id": "2655eP",
      "population": "MIBC",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "VOCALIZE",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2608P",
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2679eP",
      "population": "Other",
      "line": "Not specified",
      "phase": "Not specified",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2597MO",
      "modality": [
        "PET/CT"
      ],
      "population": "Other",
      "trial_id": "2597MO",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2613MO",
      "regimen": "Nivolumab plus Ipilimumab Therapy",
      "drugs": [
        "Nivolumab",
        "Ipilimumab",
        "nivolumab"
      ],
      "biomarkers": [
        "PD-L1"
      ],
      "population": "mUC",
      "line": "1L",
      "phase": "Not specified",
      "trial_id": "COSMIC 313"
    },
    {
      "row_id": "ROW_1882",
      "regimen": "Novel Therapies",
      "population": "Other",
      "trial_id": "ROW_1882",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "2940eP",
      "regimen": "Carboplatin Dosing Optimization",
      "population": "Other",
      "trial_id": "2940eP",
      "drugs": [
        "carboplatin"
      ],
      "biomarkers": []
    },
    {
      "row_id": "ROW_2203",
      "trial_id": "ROW_2203",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_2254",
      "trial_id": "ROW_2254",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_2255",
      "trial_id": "ROW_2255",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "CN74",
      "regimen": "Clinical Nurse Specialist and Specialist Pharmacist Clinics",
      "population": "Other",
      "trial_id": "CN74",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_2874",
      "trial_id": "ROW_2874",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "ROW_3093",
      "trial_id": "ROW_3093",
      "drugs": [],
      "biomarkers": []
    }
  ],
  "tgct": [
    {
      "row_id": "2690MO",
      "regimen": "pimicotinib",
      "drugs": [
        "pimicotinib"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 3",
      "trial_id": "MANEUVER",
      "biomarkers": []
    },
    {
      "row_id": "2694P",
      "regimen": "vimseltinib",
      "drugs": [
        "vimseltinib"
      ],
      "modality": [
        "TKI"
      ],
      "population": "Other",
      "line": "1L",
      "phase": "Phase 3",
      "trial_id": "MOTION",
      "biomarkers": []
    }
  ],
  "merkel_cell": [
    {
      "row_id": "LBA56",
      "regimen": "Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab",
      "drugs": [
        "pembrolizumab"
      ],
      "modality": [
        "IO",
        "Adjuvant"
      ],
      "population": "Other",
      "line": "Adjuvant",
      "phase": "Phase 3",
      "trial_id": "EA6174",
      "biomarkers": []
    },
    {
      "row_id": "1669P",
      "population": "Other",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1670P",
      "population": "Other",
      "trial_id": "Not specified",
      "drugs": [],
      "biomarkers": []
    },
    {
      "row_id": "1739eTiP",
      "regimen": "Chemio-immunotherapy in naive advanced Merkel cell carcinoma",
      "modality": [
        "IO",
        "Chemotherapy"
      ],
      "population": "Other",
      "line": "Not specified",
      "phase": "Phase 2",
      "trial_id": "PANDORA",
      "drugs": [],
      "biomarkers": []
    }
  ]
}